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ABSTRACT 
 
Malinovskaja-Gomez., 2016. Transdermal iontophoresis – delivery control by 
ion-exchange fibers and nanocarriers. 
 
Dissertationes Scholae Doctoralis Ad Sanitatem Investigandam Universitatis Helsinkiensis, 61/2016, 
pp. 76 
ISBN 978-951-51-2441-8 (Paperback), ISBN 978-951-51-2442-5 (PDF, http://ethesis.helsinki.fi), 
ISSN 2342-3161 
 
Biological variation and poor transport efficacy are the major concerns in the 
development of novel iontophoretic drug delivery systems for the transdermal 
administration of therapeutics. One possibility to overcome these limitations would 
be to load the drug in interest into a reservoir system such as ion-exchange fibers or 
nanocarriers prior administration. More precise and homogenous control of drug 
release and the following transdermal iontophoretic permeation could be obtained as 
the transdermal device/patch would determine the rate of drug transfer instead of the 
skin, leading to smaller inter- and intrasubject variability. In addition, the range of 
molecules delivered by iontophoresis can be expanded as charges could be imparted 
to neutral drugs by encapsulating them in charged drug carriers. Other benefits 
raising from such combined systems include enhanced drug transport into or across 
the skin, improved drug stability and decreased local side effects on skin. 
 
The aim of this thesis was to study in vitro the applicability of systems that 
combine iontophoresis and either drug-loaded ion-exchange fibers or nanocarriers 
for the controlled transdermal delivery of therapeutics. 
 
Firstly, drug reservoirs based on cation-exchange fibers were utilized to retard 
drug release and provide additional control into transdermal transport of a small 
molecular drug and a peptide. The drug release kinetics could be modified by the 
choice of the fiber type or the ionic composition of the external solution. The 
application of pulsed current iontophoresis instead of conventional constant current 
led to increased transport efficiency of a cationic hydrophobic peptide that has a 
tendency to adsorb into skin and inhibit electroosmosis as its main transport 
mechanism. In addition, drug delivery systems combining iontophoresis and 
nanoencapsulation into polymeric nanoparticles or lipid vesicles for the controlled 
transdermal delivery of lipophilic or hydrophilic model compound were developed 
and tested. Although the obtained nanocarriers were considered as suitable for 
transdermal iontophoretic administration, regarding the colloidal properties, stability 
and release kinetics, no clear advantage was observed with respect to drug 
permeation from free drug formulation. Throughout the thesis, the impact of 
formulation parameters and current type on drug transport efficiency was monitored. 
Iontophoretic transdermal drug delivery from polymeric nanoparticle-based 
formulations but not from lipid vesicular nanocarriers was improved by the 
application of pulsed current. 
ii 
 
In conclusion, binding the drug molecules prior iontophoresis into reservoir based 
on ion-exchange material or nanocarriers is a promising approach to be utilized in 
controlled transdermal delivery, although the comprehensive evaluation of full 
potential of such systems tailored for specific drug warrants further investigation in 
the future. 
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1 INTRODUCTION 
 
Transdermal drug delivery route is an appealing alternative to minimize and avoid 
the limitations linked to oral and parenteral administration of therapeutics (Thomas 
and Finnin, 2004). It can overcome problems related to poor gastrointestinal 
absorption, hepatic first-pass metabolism, and variable bioavailability. In addition, 
patient compliance can be improved by reducing the frequency of the dosing due to 
the continuous input of the drug. However, since the approval of the first transdermal 
drug delivery system (TDDS) in 1979, this mode of administration has been 
clinically realized only for a limited number of drugs (less than two dozen) owing to 
the formidable barrier properties of the outermost layer of skin, the stratum corneum 
(Naik et al., 2000). Therefore, only extremely potent therapeutics possessing 
appropriate balance of hydro-/lipophilicity, small size and no charge are able to pass 
this layer passively in pharmacologically relevant amounts. In order to overcome the 
resistant barrier function of the skin and to expand the range of compounds that can 
be delivered transdermally, a number of strategies have been developed to facilitate 
the transdermal transport, either by improving the permeability properties of the 
stratum corneum or by providing a driving force acting directly on the drug (Gratieri 
et al., 2013; Parhi et al., 2012). 
 
Unlike other physical techniques that tend to disrupt the skin barrier during 
promoting the transdermal flux, iontophoresis acts on the drug molecule itself (Kalia 
et al., 2004). It applies a mild external electric current (up to 0.5 mA/cm2) to enhance 
the permeation of ionized and neutral compounds across biological membranes. The 
drug dose delivered by iontophoresis is directly proportional to the amount of charge 
passed through the skin and can be therefore controlled by the electric input of the 
iontophoretic system: current density, type of the current and the application time of 
iontophoretic treatment. Neveretheless, iontophoresis does not eliminate passive flux 
variability and, therefore, does not always achieve true controlled delivery where the 
rate of drug input is modulated in a precisely controlled manner by a patch or a 
device (Delgado-Charro and Guy, 2003; Guy and Hadgraft, 1992). Another major 
limitation is that that only charged and relatively small molecules are predominantly 
transported by the electrorepulsion mechanism that benefit the most from this 
enhancement technique.  
 
One possibility to achieve more homogenous and reproducible transdermal drug 
delivery by iontophoresis would be to load the drug into ion-exchange materials such 
as ion-exchange fibers or nanocarriers prior to the administration. Once the drug has 
been gradually released from the fiber/ nanocarriers onto skin surface or into skin, 
iontophoresis can pump it into deeper skin layers for topical or systemic purposes. 
The combination of both the systems may provide a constant rate of input into the 
systemic circulation, resulting in drug transport which is less dependent on skin 
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variables. In addition, the range of molecules delivered by iontophoresis can be 
expanded to neutral and large drugs by encapsulating them in charged nanocarriers. 
Other possible benefits from transdermal drug delivery from drug-loaded ion-
exchange fibers or nanocarriers in conjunction with transdermal iontophoresis 
include enhanced drug transport into or across the skin, improved drug stability and 
decreased local side effects on the skin. 
One of the major concerns in iontophoretic drug delivery is the low transport 
efficiency of drug molecules. Therefore, it is important to consider the impact of all 
the various formulation, electrical and biological factors involved in the process 
(Banga, 2002). A common problem in the development of formulations for 
iontophoretic drug delivery is the presence of co-ions from the buffering agents that 
are usually smaller and more mobile than the drug molecules, and will reduce the 
fraction of the current carried by the drug. Also, the choice of current type can 
significantly affect the outcome of iontophoresis. The continuous application of 
direct current iontophoresis is typically considered as the most efficient way of 
transdermal delivery as the amount of drug transported is directly proportional to the 
total amount of current passed through the skin. However, problems related to long-
term continuous use of direct current (skin polarization, risk of electrochemical 
burns) could be sometimes overcome by a current delivered in a pulsatile or 
alternating mode. Another major challenge is the delivery of large or neutral 
molecules such as peptides that are transported mainly by electroosmosis and are 
able to inhibit their own transport by neutralizing the negative charge of the skin 
membrane. 
The main goal of this thesis was to study in vitro the applicability of a system that 
combines iontophoresis and drug-loaded ion-exchange fibers or nanocarriers for the 
controlled transdermal delivery of therapeutics. Firstly, the transdermal delivery of 
small molecules and peptides were tested from a combined system of ion-exchange 
fibers and iontophoresis. The changes in mechanisms involved in the iontophoretic 
transport of cationic peptides were evaluated and different current profiles were 
tested to increase the transdermal delivery. Secondly, two different types of 
biocompatible drug-loaded nanocarriers were combined with iontophoresis – 
polymeric PLGA nanoparticles and liposomes, and the effect of nanoencapsulation 
was investigated on the model drugs´ permeation across the skin barrier. Throughout 
the thesis, appropriate strategies to enhance iontophoretic transport efficiency of 
therapeutics was set as one of the aims, while determining the impact of both 
formulation parameters and current type on transdermal drug transport. 
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2 REVIEW OF THE LITERATURE 
2.1 Transdermal drug delivery 
 
 
Transdermal drug delivery is a painless method of delivering drugs systematically by 
applying a drug formulation onto intact and healthy skin (Guy and Hadgraft, 2002; 
Williams, 2003). Topical therapy to treat local indications of skin has been practiced 
for a long period of time. With the approval of first transdermal system in 1979 − 
scopolamine patch to treat motion sickness (Shaw and Urquhart, 1979) − transdermal 
drug delivery began to foster as a systemic mode of administration for therapeutics. 
This delivery mode has a variety of advantages compared to the oral route (Prausnitz 
and Langer, 2008; Wiedersberg and Guy, 2014). It can overcome problems related to 
poor gastrointestinal absorption, hepatic first-pass metabolism, and variable 
bioavailability. Furthermore, it can lead to controlled, continuous administration of 
the drug, even in the cases of drugs with short biological half-lives. As a result, 
constant therapeutic plasma concentrations can be achieved and the frequency of the 
administration can be significantly reduced, improving patient compliance. In the 
case of toxic effects, the drug input can be terminated, which is particularly 
indispensable for drugs with narrow therapeutic window. In addition, transdermal 
systems are non-invasive and can be self-administered, and are therefore an attractive 
alternative to hypodermic injections, which are painful, generate dangerous medical 
waste and increase the risk of disease transmission by the needles. 
 
Skin is the largest and most accessible organ in the body with a surface area of 
about 2 m2, occupying about 15% of the total body weight of an average person. It is 
composed of an outermost layer, epidermis, an inner dermis and underlying 
subdermal tissue (Berti and Lipsky, 1995; Williams, 2003). Epidermis consists 
predominantly of keratinocytes (95% of cells), Langerhans cells and Merkel cells. 
The most superficial layer of epidermis, stratum corneum (also called as horny layer) 
is a dead layer of skin with a rigidly arranged “brick and mortar” structure. This least 
permeable skin layer is the ultimate stage in the differential process of epidermis, 
consisting of compressed keratin-filled corneocytes (“bricks”) anchored in a 
lipophilic matrix of ceramides, fatty acids, cholesterol and cholesterol esters 
(“mortar”). Skin appendages, including hair follicles and sebaceous and sweat glands 
occupy about 0.1 % of skin surface. 
 
The principal barrier to percutaneous absorption resides in the stratum corneum 
and there are two main routes for drug permeation (Fig. 1). The transepidermal 
pathway through epidermis can take place between the cells (intercellular) or through 
the cells (transcellular) (Williams, 2003). The contribution of these routes depends 
on the solubility, partition coefficient and diffusivity of the drug within lipid or 
protein phases (Farahmand and Maibach, 2009; Hadgraft and Guy, 2002; Vecchia 
and Bunge, 2002). The intercellular route allows the passage of lipophilic or 
 4 
 
nonpolar molecules, while intracellular route allows the transport of hydrophilic or 
polar solutes. The transappendageal route involves the drug transport through sweat 
glands and hair follicles. For a long time, skin appendages were not considered to be 
a significant transdermal penetration route, as they account for only a very small skin 
surface area. By now it has been well established that the follicular penetration route 
may be especially relevant for hydrophilic and high molecular weight molecules, as 
well as for particle-based drug delivery systems or in drug transport by iontophoresis 
(Craane-van Hinsberg et al., 1995; Knorr et al., 2009).  
 
 
Figure 1. Pathways in transdermal drug delivery. 
Although being an attractive alternative to oral and parenteral administration, the 
clinical use of the transdermal route has remained limited due to the formidable 
barrier properties of the outermost layer of skin, the stratum corneum. The 
diffusional resistance provided by this layer means that only less than 10 mg of drug 
can be delivered systematically per day using a reasonable “patch size” area for 
permeation. Therefore, only a very limited number of molecules are able to pass 
across this layer passively in therapeutic amounts.  For a drug to be a successful 
transdermal candidate certain criteria need to be met. Firstly, transdermal delivery is 
suitable only for very potent drugs (Guy, 2010). Secondly, the molecule must possess 
the necessary physicochemical properties (Table 1) in order to be transported across 
the stratum corneum (Aulton and Taylor, 2013; Naik et al., 2000). For transdermal 
delivery, the drug molecule must first pass the multiple lipid bilayers between the 
corneocytes and then the more aqueous environment of the viable epidermis to enter 
the systemic circulation. Therefore, ideally the the drug molecule should possess 
both lipoidal and aqueous solubilities: too hydrophilic compunds will not be able to 
diffuse through stratum corneum, while too lipophilic drugs will have problem with 
clearance into blood circulation. The molecular weight of the drug also impacts 
dramatically on its transport across the skin as the diffusity across the stratum 
corneum decreases as molecular volume (and hence molecular weight) increases. 
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Therefore, skin barrier prevents efficiently the entry of larger molecules such as 
peptide or proteins into body.  
 
 
Table 1. Physicochemical considerations for passive transdermal drug delivery (modified from 
Naik et al., 2000). 
 
 
 
 
 
 
 
The presently approved drugs in the United States and Europe for passive 
transdermal delivery are presented in Table 2 (Pastore et al., 2015; Wiedersberg and 
Guy, 2014). The limited number of molecules in this list reflects the major challenge 
in transdermal drug delivery – the difficulty of finding molecules both with high 
pharmacological potency and skin permeability. 
 
 
Table 2. Currently approved transdermally delivered drugs. Modified from Pastore et al., 2015 
and Wiedersberg and Guy, 2014.   
 
 
Molecular weight 400-500 Da 
Solubility in water >1 mg ml-1 
Lipophilicity 10 <Ko/w< 1000 
Melting point < 200 °C 
pH of saturated aqueous solution pH 5-9 
Drug Year of approval Indication 
Scopolamine 1979 Motion sickness 
Glycerol trinitrate 1981 Angina pectoralis 
Clonidine 1984 Hypertension 
Estradiol 1986 Female HRT 
Fentanyl 1990 Chronic pain 
Nicotine 1991 Smoking cessation 
Testosterone 1993 Hypogonadism 
Estradiol & Norethisterone Acetate 1998 Female HRT 
Ethinyl Estradiol & Norelgestromin 2001 Female contraception 
Estradiol & Levonorgestrel 2003 Female HRT 
Oxybutynin 2003 Overactive bladder 
Selegeline 2006 Depression 
Methylphenidate 2006 ADHD 
Rotigotine 2007 
Parkinson´s disease, 
Restless leg syndrome 
Rivastigmine 2007 
Alzheimer´s and 
Parkinson´s disease 
Granisetron 2008 
Chemotherapy induced 
emesis 
Buprenorphine 2010 Chronic pain 
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The influence of these physicochemical criteria can also be translated into the 
Fickian relationship that describes the passive permeation of a compound across the 
stratum corneum that serves as a rate limiting barrier in transdermal drug delivery 
(Banga, 2002; Naik et al., 2000): 
 
𝐽𝑠𝑠 =
𝐷∗𝐾𝑠𝑐/𝑣𝑒ℎ
ℎ
∗  𝑐𝑣𝑒ℎ = 𝐾𝑝 ∗ 𝑐𝑣𝑒ℎ                                                                      (Eq. 1)            
 
where Jss is the steady-state transdermal flux, D is the diffusion coefficient of the 
drug, h is the thickness of the skin, Ksc/veh is the partition coefficient of the drug 
between stratum corneum and vehicle, cveh is the concentration of the drug in vehicle 
and Kp is the permeability coefficient of the drug. As seen from this equation, the 
strategies to increase transdermal bioavailability include increasing the diffusivity of 
the drug and partitioning in the stratum corneum, and increasing the drug 
concentration in the formulation (Naik et al., 2000; Zhang et al., 2013). Overall, drug 
absorption from a transdermal delivery system involves the following steps: 1) 
release from formulation 2) penetration into the stratum corneum and 
permeation/diffusion through it, and 3) partitioning into deeper layers of skin. For 
most of the formulations, drug partitioning into the stratum corneum is the rate 
limiting step in drug permeation. The major goal in designing controlled transdermal 
delivery systems is that the patch/device, not the skin, would control the rate of drug 
transport across the skin, leading to more reproducible and safer drug delivery (Guy 
and Hadgraft, 1992; Shaw et al., 1976; Shaw and Theeuwes, 1985). 
 
 
2.2 Enhancement of transdermal permeation 
 
2.2.1 Passive and active enhancement techniques 
 
In order to overcome the formidable barrier function of the skin and to expand the 
range of compounds that can be delivered transdermally, a number of strategies have 
been developed to increase transport across or into the skin by enhancing the 
permeability properties of the stratum corneum (passive penetration enhancement) or 
providing a driving force acting directly on the drug (active penetration 
enhancement) itself (Herwadkar and Banga, 2012; Parhi et al., 2012). 
 
Passive enhancement techniques include the use of prodrugs or chemical 
enhancers.  
 The basis of the pro-drug approach is the modification of the initial 
therapeutic entity by the addition of promoiety in order to facilitate its 
permeation, although being designed later to yield the parent drug after 
enzymatic or chemical release (Sloan and Wasdo, 2007). Due to the lipid-
aqueous biphasic structure of skin, the prodrugs need to incorporate 
functional groups in the promoiety that will increase not only the lipid but 
also the aqueous solubility (Sloan and Wasdo, 2003).  
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 The most extensively investigated enhancement strategy involves the use 
of chemical enhancers which facilitate drug permeation into the systemic 
circulation by reversely compromising the barrier function of stratum 
corneum. Examples of commonly used chemical enhancers include 
alcohols, polyalcohols, pyrrolidones, sulphoxides, essential oils, fatty 
acids, surfactants, terpenes etc. Most of them have mixed mode of action, 
such as: increased fluidity of stratum corneum lipid bilayers, disruption or 
extraction of intercellular lipids, interactions with intercellular proteins, 
increased thermodynamic activity of the drug or increased stratum 
corneum hydration (Thong et al., 2007; Walters and Hadgraft, 1993). The 
major problem that constrains the use of these substances is that the 
increased permeation enhancement activity is typically closely correlated 
with skin irritation. Therefore, a great deal of research continues to 
identify generally regarded as safe (GRAS) substances with permeation-
enhancing effects or to develop new enhancers with reduced toxicity 
(Akimoto et al., 2001; Karande et al., 2005).  
 Newer innovative approaches with supramolecular structures, such as 
vesicular systems, dendrimers and microemulsions, have also been 
utilized to improve dermal or transdermal drug delivery. These systems 
do not only increase skin permeability but also drug partitioning into the 
skin (Cheng et al., 2007; Khan et al., 2015; Kogan and Garti, 2006). 
 
Active enhancement methods for transdermal delivery use some kind of external 
energy as a driving force for drug transport across skin or physical disruption the 
stratum corneum (Gratieri et al., 2013; Mitragotri, 2013). These approaches allow a 
broader class of therapeutics to be administered effectively across the skin, including 
peptides, proteins and oligonucleotides that are typically large and polar/charged. In 
addition, the active methods have the ability to provide more controlled and 
reproducible delivery compared to the passive techniques, leading to smaller inter- 
and intrasubject variability.  
 The most evolved of these technologies, iontophoresis, uses a mild 
electric current (0.5 mA/cm2 or less) to facilitate the transport of charged 
and polar molecules across the skin. Unlike all the other enhancement 
strategies, iontophoresis acts on the molecule itself by repelling the drug 
molecules as a result of an electrical potential gradient across the skin 
(Gratieri and Kalia, 2013). The drug dose delivered can be directly 
controlled by the current density, duration and profile of the current 
application.  
 Electroporation utilizes short-term (10 µs - 500 ms) high-voltage (50-
1500 V) pulses to create transient aqueous pathways in the lipid bilayer of 
the skin (Denet et al., 2004; Prausnitz, 1999). Although in vitro this 
technique has been demonstrated to be more effective than iontophoresis, 
clinical and toxicological data of transdermal electroporation in vivo has 
remained limited.  
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 Sonophoresis (or phonophoresis) refers to the use of ultrasound (sound of 
frequency greater than 20 kHz) to compromise the barrier properties of 
skin. Ultrasound enhances drug transport by combined mechanisms of 
thermal, mechanical and chemical changes in skin tissue and formation of 
small gaseous pockets (cavitation) within cells (Azagury et al., 2014; 
Oberli et al., 2014). Commonly used frequencies in sonophoresis can be 
separated as low-frequency sonophoresis (LFS; frequency 20-200 kHz) 
and high-frequency sonophoresis (HFS; frequency 0.7-16 MHz). The 
permeation enhancement by sonophoresis is dependent on the length of 
ultrasound pulse and energy dose.  
 Microneedles are small micron-sized needles that are able to painlessly 
disrupt the barrier of skin and create pores, resulting in increased drug 
penetration (Ita, 2015; Prausnitz, 2004; van der Maaden et al., 2012). 
Drugs can be delivered either by applying a drug patch at the treated site 
(“poke and patch” approach), coating the drug onto microneedles (“coat 
and poke” approach), encapsulating the drug into biodegradable 
microneedles (“poke and release” approach), or by injecting the drug 
through hollow microneedles (“poke and flow” approach). One of the 
most attractive applications of the microneedle arrays is to utilize them in 
vaccination, especially, in self-vaccination strategies. 
 High-velocity jet injectors provide a needless alternative to traditional 
injections by painlessly administering small molecules or proteins with a 
device which delivers either powders or liquids into the skin at high 
velocity (100-200 m/s). Either compressed gas or spring is used as a 
power source for jet injectors and drugs can be administered either 
intradermally, subcutaneously or intramuscularly, depending on the 
velocity of jet and the diameter of the orifice of the device (Hogan et al., 
2015; Stachowiak et al., 2009). 
 Thermal ablation is a method that facilitates the entry of drugs through 
skin by heating the surface of skin, causing a depletion of stratum 
corneum at the heating site (Shahzad et al., 2015). Methods such as laser 
or radiofrequency can be applied to result in thermal ablation. In 
radiofrequency thermal ablation skin is exposed to high frequency 
alternating current (100-500 kHz) that causes ionic vibrations in the skin, 
leading ablation of cells in that region (Levin et al., 2005; Sintov et al., 
2003). Laser ablation uses deposition of optical energy that leads to 
evaporation of water and formation of small channels in skin barrier 
(Sklar et al., 2014). P.L.E.A.S.E.® technology based on fractional laser 
technology has been successfully utilized even in the percutaneous 
delivery of therapeutic proteins and in transcutaneous immunization with 
protein antigens (Weiss et al., 2012; Yu et al., 2011).  
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2.2.2 Iontophoresis 
 
Iontophoresis is based on the general principle that like charges repel and opposite 
charges attract each other (Fig. 2). Typically, two electrode chambers are placed on 
the skin, and on the application of iontophoretic current the drug is repelled from the 
electrode of the same polarity as the charge of the drug (active electrode) and is 
driven across the stratum corneum towards the electrode of opposite polarity 
(counter-electrode). The idea of using electric current in drug delivery dates back 
already to the mid-18th century (Helmstadter, 2001). One of the first well described 
experiments of medication transfer by electricity across skin originates from 1879, 
when German Hermann Munk exposed rabbits to an electrified strychnine solution 
for 20-25 minutes, followed by spontaneous cramps. 
 
 
Figure 2. Schematic diagram of the transdermal iontophoretic delivery of a positively charged 
drug (D+). 
Along with the benefits applicable to passive transdermal delivery (bypassing 
hepatic metabolism and higher patient compliance), the additional advantages that 
iontophoretic delivery offers can be summarized as follows (Bodde et al., 1989; 
Kalia et al., 2004; Sieg and Wascotte, 2009; Singh et al., 1995): 
 Delivery of both unionized and ionized drugs  
 Suitable both for topical or systemic delivery of drugs 
 Better control over the drug dose delivered  
 Control over drug administration kinetics, enabling continuous or pulsatile 
delivery  
 Minor skin membrane disruption and irritation  
 Enhanced delivery of polar and high molecular weight compounds  
 Easy termination of drug delivery in the case of toxicity with very potent 
drugs  
 Reduced inter- and intrasubject variability 
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The main limitation for iontophoresis resides in the fact that this enhancement 
approach is restricted mainly to drugs that can be formulated in an ionized form, as 
for neutral molecules the only iontophoretic transport mechanism would be 
electroosmosis, which is much less effective than electrorepulsion (Pikal, 2001). 
Also, although mostly related to operator error or incorrect choice of electrodes 
and/or formulation composition, cutaneous adverse effects such as skin erythema, 
burns and pain have been observed occasionally (Curdy et al., 2001). Another risk is 
that material defects in the iontophoretic system could lead to toxic systemic effects 
with drugs of narrow therapeutic index (Prescrire, 2009). In addition, iontophoretic 
devices are typically more expensive than conventional topical preparations (Roustit 
et al., 2014). 
 
Iontophoresis facilities transdermal drug delivery by three main mechanisms 
(Hirvonen, 2005):  
1) Electrorepulsion (also called electromigration) that is the ordered movement of 
ions in the presence of applied electric field. Typically it is considered the most 
important transport mechanism but only charged molecules will benefit from that. 
2) Electroosmosis (also called convective solvent flow) is the flow of water across 
the skin caused by the movement of charges across a membrane under electric 
current (Kalia et al., 2004). Application of electric field across a charged membrane 
induces the movement of counter-ions that try to neutralize the membrane charge. 
Under physiological conditions the skin is negatively charged (pI=4-4.5) and acts as 
a cation-selective membrane (Marro et al., 2001). Therefore, electroosmosis 
contributes to the flux of positively charged and uncharged molecules but opposes 
negatively charged molecules (Burnette and Ongpipattanakul, 1987). Also, since the 
electrical mobility decreases with increasing molecular weight, it has been 
hypothesized that the electrotransport of larger molecules such as peptides and 
proteins is predominantly driven by electroosmosis (Kalia et al., 2004). 
3) Enhanced passive permeability of the skin by the flow of electric current, 
although typically the passive diffusion is considered negligible in the total flux of 
drug. 
 
Therefore, the total iontophoretic flux (Ji) of a compound i across the skin during 
iontophoresis is the sum of electrorepulsion (JR), electroosmosis (JEO), and passive 
diffusion (JP) contributions: 
𝐽𝑖 =  𝐽𝑅 + 𝐽𝐸𝑂 + 𝐽𝑃                         (Eq. 2) 
In more detail, the iontophoretic flux of a compound can be described by Nernst-
Planck equation (Finkelstein and Mauro, 2011): 
𝐽𝑖 = −𝐷𝑖
𝑑𝑐𝑖
𝑑𝑥
   −     
𝑧𝑖𝐹
𝑅𝑇
 𝑐𝑖𝐷𝑖 
𝑑ɸ
𝑑𝑥
   +    ʋ𝑐𝑐𝑖                                                               (Eq. 3) 
 
 
Electrorepulsion Convective 
flux 
Passive 
diffusion 
 11 
 
where Di
  is the diffusion coefficient of the compound i, ci its concentration, zi  its 
charge number, F  is the Faraday constant, R is the gas constant, T is the absolute 
temperature, ɸ is the electrical potential and ʋc is the solvent velocity. 
The efficiency of the drug transport by iontophoresis can be described by a 
transport number (td) that reflects the proportion of the current carried by the drug, as 
compared to other migrating species in formulation, and is determined by its mobility 
(µd), charge (zd) and concentration (cd) (Phipps and Gyory, 1992):            
𝑡𝑑 =
µ𝑑 ∗ 𝑧𝑑 ∗ 𝑐𝑑
∑ µ𝑖 𝑖 ∗ 𝑧𝑖∗ 𝑐𝑖
                                                                                                         (Eq. 4) 
 
The outcome of iontophoretic delivery of solutes into or across the skin can be 
affected by a number of variables, including physicochemical properties of the drug, 
formulation parameters, electrical parameters and biological parameters. These 
variables are summarized in Table 3 (Banga, 2002; Kalia et al., 2004). 
 
Table 3.  Variables affecting iontophoretic drug delivery (Banga, 2002; Kalia et al., 2004). 
Physicochemical 
properties of the drug 
Drug 
formulation 
Electrical 
parameters 
Biological 
parameters 
Molecular weight pH Electrode material Condition of skin 
Charge Co-ions Current density Age 
Lipophilicity Ionic strength Duration of application Site 
Concentration  Current profile Skin pH 
  Polarity of electrode Inta- and intersubject 
variability 
 
Different current profiles have been utilized in transdermal iontophoretic drug 
delivery. In most cases, iontophoresis is conducted with direct constant current (DC; 
polarity and density are kept constant) in continuous manner as for most compounds 
the amount of drug molecules delivered is directly proportional to the total amount 
of current passed across the skin. However, long-term treatment with DC may lead 
to skin polarization that operates against the applied electrical field and may greatly 
decrease the magnitude of effective current across the skin (Lawler et al., 1960). 
This could be avoided when the current is delivered in a periodic manner (pulsed 
current; PC) that allows the skin to depolarize during the “off periods” of the pulse, 
so that no residual charges remain in the skin by the start of the next pulse 
(Zakzewski et al., 1992). Another limiting factor for both in the use of DC and PC 
iontophoresis is the accumulation of small ions (H+ and OH-) on the electrodes that 
may cause electrochemical burns at long application times or when inappropriate 
electrode design is used (Howard et al., 1995). The periodic reversal of current 
polarity during the iontophoresis (alternating current; AC) has shown to avoid it by 
maintaining the same electrochemical environment of the solution surrounding the 
electrodes. AC can also reduce flux drift and skin to skin variability compared to 
conventional DC iontophoresis (Zhu et al., 2002).  
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Iontophoresis has been demonstrated to be an effective method to be used in the 
areas of physical therapy, diagnostic applications, treatment of hyperhidrosis with 
tap water, and transcutaneous delivery of drugs such as local anaesthetics, opioid 
analgesics and anti-inflammatory agents (Hirvonen, 2005; Kalia et al., 2004). Table 
4 presents the iontophoretic systems for topical and transdermal drug delivery that 
have currently been approved by drug authorities. In addition to these more 
established applications, iontophoresis is being currently screened for a wide range 
of therapeutics, including for cardiovascular, central nervous system and 
endocrinological applications (Roustit et al., 2014; Sieg and Wascotte, 2009). 
 
The first iontophoretic transdermal system (ITS) approved for systemic drug 
delivery was IONSYS® for the administration of opiod analgetic fentanyl (Sinatra, 
2005). This was a true improvement compared to passive patch, extending the 
applicability of transdermal drug delivery to acute pain management, and allowing 
patients to self-administer pre-programmed doses of fentanyl non-invasively through 
the use of iontophoretic technology. The first-generation fentanyl ITS was an 
integrated one-piece system; however, corrosion was detected in a small number of 
systems that could trigger the self-activation of the system, and possibly lead to 
fentanyl overdose. Therefore, a second-generation system was designed to separate 
the drug unit from the electronic circuit of the controller during manufacture and 
storage, and snapped together immediately prior to the application to the patient by a 
healthcare professional. This new design eliminated the issue of corrosion that was 
originally seen with the first-generation system, ensuring safe operation with high 
reliability (Joshi et al., 2016). 
 
Table 4. Currently approved iontophoretic systems for topical and transdermal drug delivery. 
Based on Roustit et al., 2014.  
System 
Year of 
approval 
Drug/analyte Systemic/topical Indication 
Zecuity® 2013 Sumatriptan Systemic Migraine 
Ionsys® 2006 Fentanyl Systemic Postoperative pain 
Lidosite® 2004 Epinefrine + lidocaine Local Local anesthesia 
 
 
2.2.3 Iontophoretic delivery of peptide drugs 
 
Peptides are playing an increasingly important role in modern therapy because of 
their high potency and specificity (McCrudden et al., 2013). However, due to their 
extensive gastrointestinal metabolism, they are not suitable for oral delivery and are 
nowadays administered almost exclusively by either subcutaneous, intramuscular or 
intravenous injections. Although parental administration serves the therapeutical 
purpose, this invasive method of drug administration has several shortcomings, such 
as pain and discomfort and reduced patients` compliance. Therefore, the transdermal 
delivery route offers a potential alternative for continuous and more patient-friendly 
drug delivery (Thomas and Finnin, 2004). However, the physicochemical properties 
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of peptides − high molecular weight, charge at physiological pH and hydrophilic 
nature − render them inappropriate for passive transdermal delivery.  
 
Utilization of iontophoretic enhancement to administer peptide drugs 
transdermally is an attractive opportunity but also a great challenge (Gratieri et al., 
2011; Green, 1996; Herwadkar and Banga, 2011). In addition to facilitated 
permeation of drug and more precise control over delivery, faster therapy onset and 
offset times, iontophoresis allows to customize the current profile to mimic 
endogenous secretion profile of the peptide – e.g. by applying current in intermittent 
or pulsatile modes. At the same time, one of the biggest limitations is still the low 
transport efficiency by iontophoresis, and sometimes more invasive/effective  
methods might be needed (Guy, 1996). Other hurdles that need to be overcome 
include the high vulnerability of peptidic drugs to proteolytic enzymes in skin and 
blood, short-half life, immunogenicity, and tendency to aggregate, adsorb to surfaces 
or denaturate before reaching the target in body. 
 
Another factor to be considered is that the electrotransport of large molecules 
such as peptides and proteins is predominantly driven by electroosmosis and not by 
electrorepulsion, as the electrical mobility of species decreases with increasing 
molecular weight (Guy et al., 2000). Typically, the iontophoretic flux of compounds 
increases proportionally with current density and concentration. However, certain 
cationic hydrophobic peptides (e.g. LHRH and somatostatin analogues) have 
behaved unexpectedly during iontophoretic delivery (Delgado-Charro et al., 1995; 
Hoogstraate et al., 1994; Lau et al., 1994; Lu et al., 1993; Schuetz et al., 2005c). It 
has been shown that peptides containing adjacent cationic and lipophilic residues are 
able to associate to the negatively charged groups of the skin (Hirvonen et al., 1996). 
This could result in the neutralization of the membrane to a varying extent, causing a 
significant reduction in the normal anode-to cathode electroosmotic flow and also in 
the peptide transport. The magnitude of such electroosmotic inhibition is usually 
dependent on the amount of peptide in the skin, and therefore, the effect is often 
pronounced at higher applied current densities and increased peptide concentrations. 
In several cases, this problem has been overcome by the application of PC 
iontophoresis instead of traditional DC. Improved delivery with PC as compared to 
DC has been reported with vasopressin (Singh et al., 1998), buserelin (Knoblauch 
and Moll, 1993), nafarelin (Raiman et al., 2004) and insulin (Chien et al., 1989) due 
to the enhancement of electroosmotic solvent flow and improved drug stability. 
 
 
2.3 Ion-exchange fibers 
 
2.3.1 General aspects 
 
Ion-exchange materials are insoluble polymers that have the ability to exchange 
counter-ions within external liquid phases surrounding them (Harland, 1994; 
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Helfferich, 1995). Typically they consist of polymeric backbone (polystyrene or 
polymethacrylic polymers) onto which acidic or basic ion-exchange groups have 
been grafted. The ion-exchange materials can be either cation- or anion-exchangers, 
depending on whether they contain negatively or positively charged groups. Within 
both categories the ion-exchangers can be further classified as strong or weak 
exchangers, depending on their affinity for the soluble counter-ions. Ion-exchange 
materials containing sulfonate (–SO3−) and phosphorate acid (–PO3−) groups and 
those containing tetraammonium (–NR3+) basic groups are strongly acidic and 
strongly basic exchangers, respectively. Materials containing phenolic (–OH) groups 
and primary and secondary amine (–NH2, –NRH) groups are weakly acidic and 
weakly basic exchangers, respectively. Carboxyl groups (–COO−) and tertiary amine 
(–NR2) groups take a medium position between strong and weak acidic and basic 
exchangers, respectively. Therefore, the exchangeable mobile counter-ions in cation-
exchange materials are cations and in anion-exchange materials anions. A small 
amount of mobile ions with the charge of the same sign as the ion-exchanger (co-
ions) can also be present in the ion-exchanger. 
 
Physically the ion-exchange materials are available in various morphologies, 
including macroreticular resins, fibers, gels and membranes (Harland, 1994; 
Helfferich, 1995). The oldest and still the most used ion-exchange materials are ion-
exchange resins that are first prepared as small spherical polymeric beads (0.5-1.2 
mm in diameter) that are then chemically modified to introduce the acid or base 
functionality (Anand et al., 2001; Elder, 2005). The beads consist of three-
dimensional network of hydrocarbon chains that are inter-connected covalently by 
cross-linking. The degree of cross-linking is controlled by the percent of cross-
linking agent such as divinylbenzene (DVB) used during copolymerization. 
Although the ion-exchange resins are insoluble in all physiological media, the 
fraction of cross-linkage determines to what extent the resin can swell and shrink. 
The very first ion-exchange resin was prepared in 1935 by Adams and Holmes, and 
since then the ion-exchange resins have paved their way for various applications in 
industries such as pharmaceutical, food processing, chemical synthesis, biomedical, 
water treatment and chromatography. 
 
The concept of developing fibrous ion-exchangers (ion-exchange fibers) was first 
reported over 40 years ago by Economy and co-workers (Economy et al., 2002). 
Unlike ion-exchange resins, the fibers do not have crosslinked polymeric framework 
(Ekman, 1994). Typically, the backbone of the fibers consists of hydrophobic 
polymer chains (e.g. polypropylene, polyethylene) onto which the positively or 
negatively charged groups are grafted (Fig. 3). Fibrous ion-exchange materials have 
several advantages over conventional ion-exchange units (Economy et al., 2002; 
Kosandrovich and Soldatov, 2012; Sundell et al., 1995; Yuan et al., 2014). Ion-
exchange fibers are fabricated in the form of felts or fabrics where the contact 
efficiency with the media is improved. Due to the non-crosslinked network and 
higher surface area of the fiber compared to resin, higher rates of ion-exchange can 
be obtained. Other benefits include good mechanical strength, chemical inertness of 
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the framework, easier loading of large molecules, possibility to achieve high loading 
capacity and versatility provided by the fibrous form. 
 
 
 
 
Figure 3. The distinction in structure between ion-exchange resin and fiber. 
 
2.3.2 Theory of ion-exchange 
 
An ion-exchange reaction may be defined as the reversible stoichiometric 
interchange of ions between a solid phase (the ion-exchanger) and a solution phase, 
the ion exchanger being insoluble in the medium in which the exchange is carried 
out (Harland, 1994; Helfferich, 1995). Most importantly, electroneutrality is 
preserved at all times in both the exchanger and external solution phases, and this in 
turn requires that counter-ions are exchanged in equivalent amounts. A cation-
exchange and anion-exchange reactions may be represented as following: 
 
Cation-exchange reaction:   M-A+ + B+            M- B+ + A+ 
Anion-exchange reaction: M+A- + B-             M+B-  + A-  
 
The kinetics of ion-exchange process combines both diffusion and chemical 
reaction kinetics and is dependent on the physical nature of the ion-exchange 
material (Harland, 1994; Helfferich, 1995; Lito et al., 2012; Yuan et al., 2014). As in 
ion-exchange resins, the ion-exchange takes place in the pores and channels of the 
resin, the diffusion of counter-ions is frequently the rate-determining step in ion-
exchange processes, occurring simultaneously in both the ion-exchanger and in the 
solution. Therefore, the kinetics of ion-exchange resin can be controlled by either 
interparticle diffusion (film diffusion) or intraparticle diffusion (particle diffusion) 
or, in intermediate cases, by a combination of both the steps. Controversially, due to 
the nonporous framework of ion-exchange fibers, the ion-exchange is inclined to be 
controlled by an ionic reaction process instead of a diffusion process.  
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 According to a theory proposed by Bauman and Eichorn, the driving force for the 
ion-exchange is Donnan potential, i.e. the electrical potential difference between the 
ion-exchanger and the external liquid phase (Gregor, 1951; Helfferich, 1995; 
Philipse and Vrij, 2011). The created Donnan potential leads to the interchange of 
mobile counter-ions between these two phases until the equality of electrical 
potentials is reached for each ion (Donnan equilibrium).  This equilibrium of the ion-
exchange reaction between the ion-exchanger and external solution phases results 
both from electrostatic and hydrophobic interactions (Helfferich, 1995; Kankkunen, 
2002; Ramirez et al., 2002). The electrostatic interactions can be expressed by 
electrical partition coefficient: 
𝐾𝑒 = 𝑒𝑥𝑝 (
−𝑧𝑖𝐹ɸ𝐷
𝑅𝑇
)                           (Eq. 5)                                                              
where F is the Faraday constant, R gas constant, and T the absolute temperature. ɸD 
is defined as the Donnan potential, i.e. the electrical potential difference between the 
ion-exchanger and the solution phase. For cation-exchange materials ɸD <0 and Ke >0 
and for anion exchangers ɸD>0 and Ke<0. Similarly, the chemical partition 
coefficient can be determined as: 
𝐾𝑐 = 𝑒𝑥𝑝 [
(µ𝑖
0− µ𝑖
0
)
𝑅𝑇
]                                         (Eq. 6) 
where µ𝑖
0 and  µ𝑖
𝑜
  stand for the standard chemical  potential of the ion in the external 
liquid and ion-exchanger phases, respectively. The chemical partition coefficient 
depends on the hydrophobicity of the counter-ion. The more hydrophobic the 
counter-ion, the larger is the value of Kc (Kc>1). As the chemical partition coefficient 
is also dependent on moisture content of the material, for hydrophilic drugs the value 
of Kc can be <1. Taken together, the total ion-exchange equilibrium constant is a 
product of both of electric and hydrophobic interactions:  
𝐾 = 𝐾𝑒𝐾𝑐                                           (Eq. 7) 
 
 
2.3.3 Applications of ion-exchangers in drug delivery 
 
Ion-exchange materials have a variety of pharmaceutical applications in oral, nasal, 
and ophthalmic or transdermal drug delivery systems, either as an excipient or 
pharmacologically active ingredient (Anand et al., 2001; Elder, 2005; Guo et al., 
2009).  
 
Taste masking 
At the pH of saliva (6.8) the drug-ion-exchange resin complex remains intact, so the 
bitter taste of the drug cannot be sensed. Once the complex enters the gastrointestinal 
tract, the environment changes to acidic and drug is released. Examples of successful 
taste masking include polyacrylic cation-exchange resins in masking the bitter taste 
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of diphenhydramine hydrochloride and Carbopol of erythromycin and 
clarithromycin (Bhise et al., 2008; Lu et al., 1991). 
 
Controlled or sustained release systems 
Due to the polymeric (physical control) and ionic (chemical control) properties of 
ion-exchange materials, the drug-release can be better controlled than by other 
matrix systems that only possess physical control properties (Anand et al., 2001). 
Therefore, because of advanced drug-retaining and prevention of dose dumping, 
these materials have found an important place in the development of controlled and 
sustained release systems. Variety of different modified release systems, including 
liquid preparations, microparticles, coated complexes (e.g. Pennkinetic systems) and 
hollow fiber sytems have been designed, utilizing ion-exchange materials (Hussain 
et al., 1989; Junyaprasert and Manwiwattanakul, 2008; Raghunathan, 1980). 
 
Gastric retentive systems 
Prolonged gastric retention time of a drug formulation could significantly improve 
the bioavailability of drugs that are predominantly absorbed from the stomach. The 
ion-exchangers have been utilized for that purpose either as floating systems, 
consisting of a bicarbonate-charged resin that releases carbon dioxide that causes the 
system to float in stomach (Atyabi et al., 1996) or because of electrostatic 
interactions with mucin and epithelial cell surface (mucoadhesion) (Jackson et al., 
2001). 
 
Stability enhancement 
The drug-ion-exchanger complex can sometimes be more stable than the original 
drug. This approach has been utilized to increase the shelf-life of vitamin B12 and 
nicotine containing products (Bouchard et al., 1958). 
 
Disintegration enhancement 
Ion-exchange resins can be used as tablet disintegrating agents, because of their 
excellent swelling properties when immersed in water. Weak cation-exchange resin, 
Amberlite IRP-88 has been widely studied for that purpose (Khan and Rhodes, 
1975). 
 
Dissolution enhancement 
In the case of poorly soluble ionizable drugs, the release of the drug from drug-ion-
exchanger complex can be faster than the rate of dissolution of the solid form of the 
drug. Therfore, drug-ion-exchanger complexes can be applied to increase the rate 
dissolution of poorly soluble drugs. Firstly, ion-exchanger resin matrices are 
relatively hydrophilic and allow fast hydration of the complex. Moreover, the drug is 
molecularly distributed within the complex and there is no need to overcome crystal 
lattice energy for dissolution (Guo et al., 2009).  
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Ophthalmic or nasal DDSs 
Ion-exchangers have also found application in ophthalmic drug delivery systems 
(DDSs). For example, an ophthalmic suspension allowing sustained release of active 
ingredient (betaxolol hydrochloride), and containing cation-exchange resin 
Amberlite IRP 69 for enhanced bioadhesion, has been approved to be used in the 
treatment of glaucoma (Jani et al., 1994). Increased drug bioavailability, ocular 
comfort and uniform dosing were observed in glaucoma patients. Attempts have 
been made to deliver nicotine through nasal mucosa from a composition based on 
drug-ion-exchanger complex. For that purpose, a novel nasal formulation, in the 
form of a nicotine - Amberlite resin complex powder, was developed to provide an 
optimal combined pulsatile and sustained nicotine plasma profile for smoking 
cessation (Cheng et al., 2002). 
 
Ionic strength and pH-responsive membrane bags 
Ion-exchange membranes are ion filters of selective permeability that in vivo act 
depending on the pH at the site, ionic strength and drug properties. This principle has 
been utilized for example in pulsatile and site-specific delivery of gastric acid 
inhibitors, nitrates, hormone replacement therapy, insulin and immunization 
(Akerman et al., 1998; Ito et al., 1989). 
 
Implantation devices 
Ion-exchange materials can be used to enhance the delivery of water soluble or 
charged drugs from silicone implantation devices, as they produce additional force 
that reduces the activation energy for each ion to permeate the membrane (Christy et 
al., 1979). 
 
Topical applications 
The inclusion of ion-exchange resins into topical products, such as ointments, 
creams, and lotions, has been shown to be advantageous because of their high 
buffering and adsorption capacity, lack of dermal irritancy, inability to permeate into 
the skin and flux modification, as the drug-resin complexes act as reservoirs on the 
skin (Elder, 2005). 
 
Therapeutically active agents 
Certain ion-exchange resins have found utility as drugs in their own right. Anion-
exchangers cholestyramine and cholestipol are currently used in the treatment of 
type II and familial hyperlipotroteinemia, lowering low-density lipoprotein 
cholesterol (LDL-C). They bind and remove bile acids from the gastrointestinal tract 
that in turn forces the liver to consume more cholesterol in order to produce more 
bile acids (Goodman et al., 2006). Cation-exchange resins have been utilized in 
conditions of sodium- and water-retention such as cardiac failure, liver cirrhosis, 
toxaemia of pregnancy and nephrotic syndrome. Also, in the management of drug 
poisoning (e.g. hyperkalaemia) and hemoperfusion ion-exchange resins have 
demonstrated their potential (Payne, 1956). 
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2.4 Nanocarriers for transdermal delivery 
 
2.4.1 General aspects about nanocarriers 
 
Nanotechnology can be defined as a science of engineering of functional systems at 
the molecular scale (Bamrungsap et al., 2012). As such systems possess unique 
physical, optical and electronic features, they are attractive for disciplines such as 
nanomedicine and drug delivery, which try to apply nanotechnogical approaches for 
the prevention, diagnosis and treatment of diseases. Nano-sized drug delivery 
systems – nanocarriers – have been developed where drugs are absorbed or 
conjugated onto the carrier surface, encapsulated inside a polymer/lipid or dissolved 
within the carrier matrix (Biswajit et al., 2014). 
 
The term “nanoscale” typically refers to particle size below 100 nm, but for the 
purpose of drug delivery, carriers in the size range of 50-500 nm can be acceptable, 
depending on their route of administration (Cevc and Vierl, 2010). Due to their small 
size, new properties arise which have made nanosystems attractive drug delivery 
platforms for formulation scientists. Firstly, the large surface area helps to bind, 
adsorb and carry drugs, probes and proteins. Furthermore, bound or encapsulated 
into the nanocarrier, drugs can be protected from a hostile environment or their 
unfavorable biopharmaceutical properties can be masked and replaced with the 
properties of the carrier. In addition, nanocarriers can accumulate preferentially at 
tumor, inflammatory, and infectious sites due to the enhanced permeability and 
retention (EPR) effect. The EPR effect includes site-specific characteristics, not 
associated with normal tissues or organs, thus resulting in increased selective 
targeting. Based on those features, the application of nanocarriers in drug delivery 
offer many several benefits, including (1) improvement in drug biodistribution and 
pharmacokinetics, leading to higher efficacy of drugs; (2) reduction of adverse 
effects as a consequence of favored accumulation at target sites; (3) improvement in 
stability of drugs, increasing the range of drugs suitable for administration, and (4) 
decrease in toxicity by using biocompatible nanomaterials (Bamrungsap et al., 2012; 
Biswajit et al., 2014)   
Although, the primary focus for the use of nanocarriers is placed on the parenteral 
and peroral applications, other routes such as ocular and transdermal are gaining 
more attention. Among many others, the nanocarriers most used and investigated in 
the pharmaceutical field include nanocrystals, polymeric nanoparticles, inorganic 
nanoparticles, solid lipid nanoparticles, quantum dots, dendrimers, liposomes, 
microemulsions, protein-based nanoparticles, and hydrogel nanoparticles. 
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2.4.2 Nanocarriers in skin delivery 
 
In recent years, the transcutaneous utilization of drug-loaded nanocarriers has 
increasingly gained a lot of attention in order to obtain local drug effect on skin 
(dermal drug delivery) or systemic drug delivery accompanied by the drug 
permeation across the skin (transdermal drug delivery). The development of such 
systems has, in one way or another, addressed the shortcomings of traditional drug 
delivery systems used for (trans)dermal applications. The most used or investigated 
nanocarriers for dermal/transdermal drug delivery include liposomes and other 
vesicular systems, dendrimers, microemulsions, solid lipid nanoparticles and 
polymeric nanoparticles (Cevc and Vierl, 2010; Khan et al., 2015; Neubert, 2011). 
 
Again the main challenge in the development of such dermal/transdermal systems 
is how to overcome the tight barrier function of stratum corneum. As nanocarriers 
present a group of highly heterogeneous systems, no straightforward generalizations 
of intact carrier penetration can be made. The compositions and, with respect to that, 
the physicochemical properties of the nanocarriers (size, shape, flexibility and 
surface charge) determine the interactions with the skin barrier. Overall, there are 
three potential targeting sites for nano-sized carriers, which include the epidermis, 
skin furrows or the hair follicles (Prow et al., 2011). It is generally agreed that 
nanocarriers cannot penetrate epidermis and reach deeper layers of skin intact 
without barrier modification (EC, 2008). There is evidence of some skin penetration 
for very small particulate carriers (<10 nm), but data of carriers larger than that is 
controversial and discussion still ongoing. Naturally, in the case of compromised or 
diseased stratum corneum, there might be a potential for bigger particle penetration. 
Among the lipid-based nanocarrier systems, ultradeformable vesicles 
(transfersomes) have been reported to invade the skin deep enough to be detected in 
the systemic circulation (Cevc et al., 2002). It has been claimed that hair follicles 
could be ideal reservoirs for drug-loaded nanocarriers, since the pilacebaceous unit is 
more permeable than corneocytes (Lademann et al., 2007). Follicular penetration of 
both lipid vesicles and polymeric nanoparticles up to 600 mm in size has been 
reported and it has been suggested that the movement of the hair acts as a geared 
pump to push the nanocarriers into the hair follicles (Lademann et al., 2009). 
Approaches such as skin flexing and massage can further increase the penetration 
depth of nano-sized particulates into hair follicles (Lademann et al., 2007; Tinkle et 
al., 2003). Taken together, the drug transport by nanocarriers across the skin is a 
complex process and often a combination of multiple modes, such as release of free 
drug at the skin/nanocarrier interface, adsorption and fusion of the carrier onto skin 
surface, penetration of the carrier across the stratum corneum, mixing of carrier 
constituents with skin lipids, increase in drug partitioning into the skin, formation of 
drug depot in hair follicles or interaction of special chemical composition of 
nanocarrier with lipid/protein domains of the stratum corneum, leading to enhanced 
permeability (Khan et al., 2015; Schroeter et al., 2010). 
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The use of topically applied nano-sized carriers have several advantages over the 
conventional formulations for dermal applications, including readily-tunable 
chemical and physical features, possibility to protect unstable drugs from 
degradation/denaturation, decrease in local side effects such as skin irritation, 
possibility to provide more localized therapeutic effect, and enhancement of 
cutaneous penetration of the drugs across the skin barrier by increasing the 
concentration gradient (Zhang et al., 2013). Also, combining of nanotechnology and 
active enhancement techniques, such as microneedles, electroporation and 
iontophoresis, are deemed to be the future goal for facilitating even more the 
transdermal delivery of drugs (Khan et al., 2015). The main limitation in the wider 
use of nano-sized carrier systems is the overriding concern about the safety of such 
systems, recognizing the possibility that the non-biodegradable nanocarrier might be 
taken up and be retained in the reticulo-endothelial system. In addition, there is the 
environmental burden that needs be considered when it comes to any nanomaterial. 
Finally, the scale-up of the production of such nanocarriers can be rather 
complicated and expensive (Prow et al., 2011). 
 
 
 
2.4.3 PLGA nanoparticles 
 
Poly(lactic-co-glycolic acid) (PLGA) is a copolymer of polylactic acid (PLA) and 
polyglycolic acid (PGA) polymers (Fig. 4). It is one of the most widely used 
polymers for the production of nanoparticles because of its biodegradability by the 
hydrolysis of the polymer resulting in lactic and glycolic acids which are natural 
metabolites found in the body. Besides that, the PLGA nanoparticles have other 
advantages over other polymeric nanocarriers (Danhier et al., 2012; Lai et al., 2014). 
The high purity of these synthetic polymers makes the preparation of nanoparticles 
more reproducible. By varying the molecular weight and copolymer ratio, the 
degradation of the particles can be modified from months to years. By a choice of 
the preparation method and parameters, hydrophobic or hydrophilic small or 
macromolecular drugs can be encapsulated, and different physical characteristics can 
be synthesized for the nanoparticles (size, size distribution, morphology and zeta-
potential). Furthermore, the surface properties can be easily modified to impart a 
targeting ligand or a desired function. Owing to these properties, PLGA has been 
approved by the US FDA and European Medicine Agency (EMA) to be used on 
humans in various drug delivery systems. 
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Figure 4. The chemical structure of poly(glycolic acid) (PGA), poly(lactic acid) (PLA), and 
poly(lactic-co-glycolic acid) (PLGA). 
Therefore, biodegradable PLGA nanoparticles have been investigated for 
sustained and targeted/localized delivery of different compounds (small molecular 
weight drugs, proteins and peptides, plasmid DNA) in various biomedical 
applications, such as vaccination, treatment of cancer, cerebral, cardiovascular or 
inflammatory diseases, or in regenerative medicine (Danhier et al., 2012; Lu et al., 
2009). The applications regard mostly parenteral or oral routes, but in the field of 
transcutaneous drug delivery their potential appears to be rather unexplored.  
 
The rationale behind using polymeric (including PLGA nanoparticles) drug-
loaded particles on skin for dermal/transdermal delivery are: (1) effective 
enhancement of the skin permeation of therapeutics, especially for the poorly water-
soluble lipophilic drugs; (2) improvement in the drug stability; (3) decrease in side 
effects such as skin irritation of applied drugs, and (4) possibility for more localized 
effect and minimized systemic exposure (Zhang et al., 2013). Most of the reports on 
the drug-loaded PLGA nanoparticles utilizing transcutaneous route have shown 
effective delivery of therapeutics for local therapy. Successful dermal delivery by 
these nanocarriers has been reported for nonsteroidal anti-inflammatory drugs 
(Abrego et al., 2016; Luengo et al., 2006; Parra et al., 2016; Vega et al., 2013), 
photosenitisizers (da Silva et al., 2013), corticosteroids (Ozcan et al., 2013) or 
hairgrowth inducing agents (Tsujimoto et al., 2007). PLGA nanoencapsulation has 
also demonstrated potential in areas like dermal wound healing therapies (Chereddy 
et al., 2013; Losi et al., 2013) and transcutaneous vaccination (Mittal et al., 2013). 
The findings from a study by Raber et al. (2014), where the effect of surface 
modification of PLGA nanoparticles on the nanoparticle uptake into hair follicle was 
investigated, could be used to optimize drug targeting by that route (Raber et al., 
2014). In general, although applicable to local delivery, in order to transport drugs 
into the deeper layers of skin or for systemic purposes, drug-loaded PLGA particles 
have to be combined with some active enhancement methods such as microneedles 
(Zhang et al., 2010), needle-free jet injector (Michinaka and Mitragotri, 2011) or 
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iontophoresis (Tomoda et al., 2011). Even more, DNA delivery by gene gun from 
PLGA nanoparticles has been investigated (Lee et al., 2010). 
 
 
2.4.4 Liposomes    
 
Liposomes are nano-sized vesicles that contain amphipathic phospholipids arranged 
in one or more bilayers enclosing an equal number of aqueous compartments. 
Depending on the physicochemical properties, drugs can be intercalated into the 
lipid bilayer (lipophilic compounds) or in the aqueous core (hydrophilic compounds) 
(Pierre and Dos Santos Miranda Costa, 2011).  
 
Liposomes have demonstrated great potential as drug carrier systems to be 
delivered by various routes of administration, including onto skin. Topically 
administered liposomal formulations can exhibit either a localized effect with 
augmented deposition of drug on the site of action or they can provide targeted drug 
delivery through skin appendages (Zhai and Zhai, 2014). Potential advantages of 
topical liposome use include enhanced drug delivery, solubilization of poorly soluble 
drugs, drug protection against proteolytic degradation, local skin depot for sustained 
release, reduction of side-effects and incompatibilities, or the formation of rate-
limiting barrier for systemic absorption (Weiner et al., 1994). But at the same time it 
is generally agreed that conventional liposomes have little or no value as carriers for 
transdermal delivery as they do not penetrate the skin but rather remain in the upper 
layers of stratum corneum (Pierre and Dos Santos Miranda Costa, 2011). Therefore, 
specially designed vesicular carriers, such as ethosomes, transfersomes, niosomes, 
invasomes, polymerosomes etc., have been developed to improve drug permeation 
through the skin (Fig. 5). The mechanism by which vesicular systems increase the 
concentration of therapeutics in epidermis or deeper layers of skin are still under 
investigation. Different mechanisms of action have been proposed, such as free drug 
permeation after release from the vesicular system, penetration enhancing effects of 
liposomes, and adsorption/fusion with skin lipids (Schroeter et al., 2010). 
Discussions are still ongoing whether liposomes or similar vesicles are penetrating 
skin as intact aggregates or the liposomal lipids are incorporated into the ones of 
stratum corneum. 
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Figure 5. Different types of lipid-based vesicular delivery systems used in transdermal drug 
delivery. 
From the vesicular systems, ethosomes and transfersomes have shown the highest 
potential in transdermal drug delivery. Ethosomes are flexible, soft liposomes that 
contain 20-45% of ethanol (Touitou et al., 2000). They have been reported to 
increase skin permeability by a tentative synergistic “ethanol-ethosome effect” in 
which ethanol disrupts the organization of stratum corneum lipid bilayer, allowing 
the flexible ethosomes then to penetrate and possibly permeate this layer. 
Transfersomes (also called as ultradeformable liposomes) are another type of 
modified liposomes, whose main feature lies in the inclusion of edge activator 
(surfactant such as sodium cholate, sodium deoxycholate, Span-80, Tween-80) into 
lipid bilayer, promoting elasticity and deformability (Cevc and Blume, 1992). As the 
basic driving force for the transfersomes to penetrate the skin was found to be the 
hydration gradient between skin surface and the inside, non-occlusive conditions are 
a prerequisite for their barrier penetration. The enhanced transdermal delivery by 
niosomes, the non-ionic surfactant vesicles, has been proposed as a result of the 
vesicles mixing with the skin lipids in the intercellular layers (Uchegbu and Vyas, 
1998). Invasomes, containing ethanol and terpenes, combine the synergistic effects 
of both constituents in penetration enhancement (Dragicevic-Curic et al., 2008). 
Polymersomes are vesicular aggregates containing self-assembling block-co-
polymers instead of lipids that have also potential for transdermal delivery because 
of flexibility, deformability and biocompatibility (Rastogi et al., 2009). 
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2.5 Benefits from the combined use of transdermal 
iontophoresis and drug-loaded ion-exchange fibers or 
nanocarriers 
 
It is generally agreed that iontophoresis provides relatively good control over drug 
fluxes as drug transport is directly controlled by the current applied. Therefore, 
iontophoretic treatment may be safe to use even in populations of uncertain barrier 
maturity such as neonates, premature infants or on compromised skin (Hirvonen, 
2005; Sekkat et al., 2001). At the same time, iontophoresis does not eliminate the 
passive variability, and for some compounds such as nicotine the iontophoretic and 
passive contributions can be of the same order of magnitude (Brand and Guy, 1995). 
Another major limitation of iontophoresis lies in the range of molecules (charged 
molecules mainly) that can benefit from the technique. Large and neutral molecules 
demonstrate low transport numbers under iontophoretic current as for these drugs 
convective solvent flow is the main mechanism of electrotransport (Delgado-Charro 
and Guy, 2003). One possibility to overcome these two limitations would be to load 
the drug of interest into a reservoir system, such as ion-exchange fibers or 
nanocarriers, prior to the administration. The rationale behind this approach is that 
more precise and homogenous control of drug release and the following transdermal 
iontophoretic permeation could be obtained. Therefore, the transdermal device/patch 
would determine the rate of drug transfer instead of the skin, the fluxes would be 
more reproducible, leading to smaller inter- and intrasubject variability (Guy and 
Hadgraft, 1992). Firstly, the drug would be gradually released from the 
reservoir/carrier in a predetermined rate (1st flux controlling part). Once released 
onto the skin surface or into the skin, iontophoretic current (2nd flux controlling part) 
would pump the drug into the deeper skin layers for topical or systemic applications. 
In addition, the range of molecules delivered by iontophoresis could be expanded as 
charges could be imparted to neutral drugs by encapsulating them in charged drug 
carriers. 
 
While the application of ion-exchange materials as drug delivery vehicles in 
passive transdermal delivery has proven to be rather unsuccessful (Conaghey et al., 
1998), transdermal systems have been developed where iontophoresis has been 
combined with drug-loaded ion-exchange materials. Charged drug molecules have 
been electrostatically bound to the ion-exchange groups of ion-exchangers prior to 
administration and then gradually released by mobile counter-ions and transported 
across the skin by the iontophoretic current. By the selection of suitable external 
conditions, ion-exchanger and drug properties (Table 5), the drug release kinetics 
from the ion-exchange system and drug permeation could easily be optimized to 
required needs (Hirvonen, 2005). Such systems combining ion-exchange materials 
and iontophoresis have been successfully utilized in both transscleral (Li et al., 2006) 
and transdermal iontophoretic drug delivery (Kankkunen et al., 2002b; Xin et al., 
2012; Xu et al., 2009). Transdermal drug transport from ion-exchangers under 
iontophoretic treatment in vitro or in vivo has been investigated for a variety of 
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different drugs, including nicotine, beta blockers, NSAIDs, opioids and therapeutics 
used in the treatment of neurodegenerative diseases (Conaghey et al., 1998; Gao et 
al., 2014; Jaskari et al., 2000; Kankkunen et al., 2002a; Kankkunen et al., 2002b; Xin 
et al., 2012; Xin et al., 2014; Xu et al., 2009; Yu et al., 2006). The successful in vivo 
delivery of  anti-Alzheimer drug tacrine from cation-exchange fibers has been 
demonstrated in humans (Kankkunen et al., 2002b). 
 
Table 5. Factors affecting the binding and release of a drug into/from ion-exchanger (Akerman et 
al., 1998; Helfferich, 1995; Hänninen, 2008; Kankkunen, 2002; Vuorio, 2004) 
Properties of the 
ion-exchanger 
Properties of the 
drug 
Properties of the 
external solution 
Ion-exchange capacity pKa pH 
Nature of ion-exchange 
groups 
Lipophilicity Ionic strength 
Particle size Size Temperature 
Degree of cross-linking Solubility Valence of counter-ions 
Preloaded counter-ion Sterical properties 
Concentration of counter-
ions 
 
Concentration in 
ion-exchanger 
Selectivity of counter-ion 
 
Similarly, drug-loaded nanocarriers could be combined with iontophoresis in 
transdermal delivery. The drug loaded carriers could create a drug reservoir on the 
surface of the skin and/or in the hair follicles; from this reservoir, the drug would be 
slowly released to the surface of the skin and into the deeper skin layers; and once 
released, the iontophoretic current could carry the drug across the skin into the 
systemic circulation. Although there are many reports on the separate use of 
nanocarriers and iontophoresis for skin penetration enhancement, the combined use 
of both the approaches has remained rather unexplored. There are only few reports 
where transdermal iontophoresis was combined with polymeric nanoparticles 
(Tomoda et al., 2011, 2012a; Tomoda et al., 2012b), solid lipid nanoparticles 
(Charoenputtakun et al., 2015; Liu et al., 2008), dendrimers (Mutalik et al., 2013), 
microemulsions (Boinpally et al., 2004; Kantaria et al., 1999; Sintov and Brandys-
Sitton, 2006), nanovesicles (Boinpally et al., 2004; Chen et al., 2009) or  liposomes 
(Essa et al., 2002a, b, 2004; Fang et al., 1999; Han et al., 2004; Kajimoto et al., 
2011; Kigasawa et al., 2012; Vutla et al., 1996).  
 
Several advantages over conventional formulations/vehicles have been reported 
on the iontophoretic drug delivery from the drug-ion-exchange fiber complexes or 
drug-loaded nanocarriers: 
 
 Enhanced drug delivery into or across the skin 
Significant improvement of systemic drug permeation has been demonstrated in 
several studies by combining ion-exchange materials as drug reservoirs (Xin et al., 
2012; Xu et al., 2009) or drug-loaded nanocarriers, such as polymeric nanoparticles 
or lipid vesicles (Essa et al., 2002b; Tomoda et al., 2011; Tomoda et al., 2012b) with 
iontophoretic treatment. Also higher follicular accumulation of the drug for the 
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dermal delivery has been reported when iontophoresis has been combined with 
nanocarriers (Han et al., 2004). 
 
 Better flux control 
Combining iontophoresis with drug-loaded reservoir or carrier system from where 
the drug is gradually released at a predetermined rate could lead to more predictable 
and controlled drug transport, resulting in fluxes less dependent on skin variables.  
 
 Improved drug stability 
Binding the drug into the ion-exchange material or encapsulating it into nanocarriers 
could also be used as a strategy to stabilize the drug until it is gradually released into 
the surrounding solution at the time of the application. This was shown with an 
easily oxidizing drug levodopa that was attached to ion-exchange fibers in an acidic 
solution (Kankkunen et al., 2002a) or when enkephalin was incorporated into 
liposomes (Vutla et al., 1996). 
 
 Reduced local toxicity 
Due to the enhanced drug delivery, skin irritation could be minimized as shorter 
application times of the iontophoretic current are needed or the amount of 
permeation enhancing excipient in the formulation might be reduced for the 
equivalent drug dose delivered. 
 
 Possibility to deliver neutral/large molecules by iontophoresis 
Neutral and large molecules that are difficult to deliver by iontophoresis as their 
transport is dependent on the electroosmosis could be encapsulated into charged 
nanocarriers in order to improve the transport efficiency. This approach has been 
utilized with a neutral molecule colchicine or large molecules such as insulin or 
superoxide dismutase that were encapsulated into cationic liposomes prior to the 
iontophoretic administration (Kajimoto et al., 2011; Kigasawa et al., 2012; Kulkarni 
et al., 1996) 
 
 Entrapment of counter-ions 
Ion-exchange materials can be used in transdermal iontophoretic delivery to capture 
competing endogenous counter-ions for better drug transport efficiency or pH 
control over the formulation (Conaghey et al., 1998; Xu et al., 2009). 
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3 AIMS OF THE STUDY 
 
The main aim of this thesis was to evaluate the potential of the combined use of 
iontophoresis and drug-loaded ion-exchange reservoir or carrier systems for the 
controlled transdermal delivery of therapeutics.  
 
More specifically, the aims of the study were: 
 
 To investigate the applicability of drug delivery systems that combine 
transdermal iontophoresis and ion-exchange fibers as drug reservoirs for the 
administration of either small molecular compounds or peptides (I, II). 
 
 To evaluate the transport mechanisms involved in the iontophoretic drug 
delivery of peptidic drug leuprorelin acetate (II). 
 
 To investigate the applicability of drug delivery systems that combine 
transdermal iontophoresis and drug nanoencapsulation. More precisely, the 
goal was to investigate drug transport from charged biocompatible 
nanocarriers such as PLGA nanoparticles and liposomes (III, IV). 
 
 To determine the effect of formulation parameters and current type of the 
iontophoretic system on the transdermal drug transport (I, II, III, IV). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 29 
 
4 EXPERIMENTAL 
 
Complete details of all the materials, equipment and methods used in this work can 
be found in the respective original publications (I-IV). 
 
 
4.1 Materials (I-IV) 
 
Apomorphine hydrochloride hemihydrate (I), flufenamic acid (III), diclofenac 
sodium (IV) were obtained from Sigma Chemical Co. (St. Louis, MO, USA), 
leuprorelin acetate (II) from ChemPep® (Wellington, FL, USA) and acetaminophen 
(II) from Hawkins Inc. (Minneapolis, MN, USA). Chemical structures of the model 
drug compounds and their most important physicochemical properties are given in 
Table 6.  
 
The cation-exchange fibers Smopex®-101 [-SO3H ion-exchange groups, styrene 
sulphonic acid grafted polypropylene fiber] and Smopex®-102 [-COOH ion-
exchange groups, acrylic acid grafted polypropylene fiber] were received from 
Johnson Matthey (I-II) (Turku, Finland). The ion-exchange capacities of Smopex®-
101 and Smopex®-102 fiber were 4.1 and 6.4 mmol/g, respectively. Poly(lactic-co-
glycolic acid) 50:50 (PLGA; Resomer® RG 503H) (III) with a molecular weight 
(MW) of 24,000-38,000 Da, polyvinyl alcohol (PVA; Mowiol® 4-88) (III), 5-
fluoresceinamine (FA) (III), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
hydrochloride (DMAP), cholesterol (Chol), Tween-80 (IV) and 4-(2-hydroxyethyl)-
1-piperazineethanesulphonic acid (HEPES) (I-IV) were obtained from Sigma 
Chemical Co. (St. Louis, MO, USA). Soya phosphatidylcholine (PC; Emulmetik 
930) (IV)  was purchased from Lucas Meyer Cosmetics (Champlan, France) and 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-
2000] ammonium salt (DSPE-PEG2000) (IV) from Avanti Polar Lipids (Alabaster, 
AL, US). All other chemicals were at least of analytical grade. Deionized water (≥ 
18.2 MΩ/cm of resistance; Millipore, Molsheim, France) was used to prepare all the 
solutions. 
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Table 6. Physicochemical properties of the drugs studied. 
Drug MW pKa logPoct Structure/ sequence 
 
 
Apomorphine hydrochloride (I) 
 
 
312.79 
 
7.2, 8.9 
 
1.76 a 
 
 
Leuprorelin acetate (II) 
 
1209.4 - 1.76 b 
 
Pyr-His-Trp-Ser-Tyr-D-Leu-
Leu-Arg-Pro-NHEt 
 
Flufenamic acid (III) 
 
281.23 3.9 5.62 c 
 
 
Diclofenac sodium (IV) 
 
 
318.13 
 
4.15 0.92 d 
 
a Corresponds to apomorphine base, experimentally determined (Drayton et al., 1990); b calculated value 
(Drugbank); c experimentally determined (Moffat, 1986); d experimentally determined (Sarveiya et al., 
2004). 
 
 
4.2 Methods (I-IV) 
 
4.2.1 Drug loading into ion-exchange fibers (I-II) 
 
In order to load drugs into Smopex®-101 and Smopex®-102 cation-exchange fibers, 
100 mg of fiber (dry content) bundles wrapped into porous gauze (Mesoft®, 
Mölnlycke Health Care, Gothenburg, Sweden) were prepared. Loading of fibers was 
conducted with 10 fiber bundles immersed in the same loading solution on a shaker 
(150 movements/min): 
 
 Loading with apomorphine was performed over 2 consecutive loading 
periods – initially for 24 h and then the bundles were transferred into fresh 
loading solution for an additional 24 h (I). 50 ml of apomorphine solutions 
pH3.0 with two different concentrations (0.1% or 0.25%) were used for 
loading.  
 Loading with leuprorelin acetate was conducted for 48 h. 30 ml of 2 mg/ml 
leuprorelin acetate solution in deionized water pH=7.4 was used as a loading 
solution (II). Prior to loading, the bundles were pre-treated with 30 ml 100 
mM NaCl/ 100 mM NaOH mixture for 30 + 30 minutes.  
 
When the effect of NaCl or HCl pre-treatment on the loading extent/ stability of 
the drug was studied, the bundles were immersed prior to the loading into 100 mM 
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NaCl for 30 + 30 minutes or 100 mM HCl for 6 + 18 hours (I). After each loading 
period, the unbound compound was washed from each bundle and the washing 
solutions were combined with the loading solution. The amount of compound loaded 
into the fiber bundles was determined by HPLC (I) or by UPLC-ESI-MS (II) as the 
difference between the amounts of compound in the initial loading solution and in 
the collected post-loading and washing solution. 
 
 
4.2.2 Preparation of PLGA nanoparticles (III) 
 
Firstly, 5-fluoresceineamine-bound PLGA (FA-PLGA) was prepared based upon the 
method described by Horisawa et al. (Horisawa et al., 2002) and Weiss et al. (Weiss 
et al., 2006). Briefly, 3.07 g PLGA, 0.0583 g FA and 0.0408 g of DMAP were 
dissolved in 30 ml of acetonitrile and incubated at room temperature for 24 h under 
gentle stirring and light protection. The resulting FA-PLGA was precipitated by the 
addition of purified water and separated by centrifugation. The polymer was rinsed 
from excessive reagents (repeated dissolution in acetone and precipitation with 
ethanol) and then lyophilized with Alpha 2-4 LSC freeze-dryer (Martin Christ 
Gefriertrocknungsanlagen GmbH, Osterode am Harz, Germany). FA-PLGA 
nanoparticles loaded with flufenamic acid (FFA) were prepared by the emulsion 
diffusion/evaporation technique. In brief, 6 mg of flufenamic acid and 50 mg FA-
PLGA were dissolved in 2.5 ml ethyl acetate. This organic solution was added 
dropwise into 2.5 ml of an aqueous solution of 2% PVA. The mixture was then kept 
for 1 hour under magnetic stirring at 600 rpm at ambient temperature. The resulting 
o/w emulsion was homogenized with Branson ultrasonifier S250D (Branson 
Ultrasonics Co., CT, USA) at 10% amplitude for 30 s. 20 ml of water was added and 
the emulsion was kept under stirring overnight to evaporate the organic solvent. For 
reference, standard drug-free FA-PLGA nanoparticles were prepared in the same 
way. The dispersions were purified using Vivaspin 20 ml ultrafiltration spin column 
(Sartorius, Goettingen, Germany) using centrifugation at 4000 rpm for 40 min and 
were further washed three times with deionized water. 1 ml of final formulation used 
in all the permeation experiments consisted of 17.86 mg FA-PLGA nanoparticles 
(containing 1 mg of FFA) suspended in 25 mM Hepes buffered saline pH=7.4. 
 
 
4.2.3 Preparation of liposomes (IV) 
 
Conventional liposomes, pegylated liposomes and transfersomes were prepared by 
the classic cast film method (Table 7). Briefly, phophatidylcholine (PC), cholesterol 
(Chol), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-polyethylene-
glycol-2000 ammonium salt (DSPE-PEG2000) and Tween-80 were dissolved in 
absolute ethanol in a clean, dry, round-bottom flask. The organic solvent was 
removed by evaporation for 20 min at 45 °C to obtain homogenous thin lipid film on 
the inner surface of the flask. The deposited film was then hydrated with 2.5 mg/ml 
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diclofenac sodium solution (DS) in 10 mM Hepes buffered saline pH=7.4 for 1 h at 
45 °C. The resulting vesicles were extruded 11 times through 100 nm polycarbonate 
membrane at 45 °C. 
 
In order to prepare ethosomes, the lipids and DS were dissolved in absolute 
ethanol. This mixture was heated to 30 °C ± 1°C in a water bath. Buffer (10 mM 
Hepes buffered saline pH=7.4), also heated to 30 °C ± 1 °C, was added slowly as a 
fine stream to the lipid mixture with constant stirring at 700 rpm in a closed vessel. 
Mixing was continued for an additional 5 minutes, while maintaining the system at 
30 °C ± 1 °C. The size of the vesicles was reduced by sonication for 15 s at 15 W, 
followed by extrusion for 11 times through 100 nm polycarbonate membrane at 
ambient temperature. 
 
Table 7. Composition of DS lipid vesicles. 
Formulation  Composition 
Conventional liposomes  
90 mM PC 
30 mM Chol 
Pegylated liposomes  
90 mM PC 
30 mM Chol 
2.5% (mol/mol%) DSPE-PEG2000 
Transfersomes  
 
120 mM PC 
15% (w/w%) Tween-80 
Ethosomes  
90 mM PC 
30 mM Chol 
20% (v/v%) ethanol 
 
 
 
4.2.4 Physicochemical characterization of nanocarriers (III-IV) 
 
The colloidal characteristics (hydrodynamic radius, polydispersity index, zeta 
potential) of the drug-loaded nanocarriers were determined by Malvern Zetasizer 
Nano (III-IV; Malvern Instruments, Malvern, UK). The morphology of the FA-
PLGA nanoparticles (III) was evaluated by FEI QuantaTM FEG scanning electron 
microscope (SEM; FEI Company, Hillsboro, OR, USA). The samples were fixed 
onto a two-sided carbon tape with silicone adhesive and sputtered with platinum for 
25 seconds with an Agar sputter device (Agar Scientific Ltd., Essex, UK) prior to 
imagining.  
 
Drug loading into the nanocarriers was assessed as follows: 
 For FA-PLGA nanoparticles, a fixed amount of purified freeze-dried 
nanoparticles was dissolved in acetone (polymer and drug both soluble) and 
then methanol was added (only drug soluble) to precipitate the FA-PLGA 
(III). The nanoparticle dispersion was centrifuged to separate the supernatant 
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and the encapsulated amount of flufenamic acid was determined by HPLC 
analysis. 
 For liposomes, the vesicle-encapsulated diclofenac sodium was separated 
from the unentrapped drug by ultracentrifugation at 30000 rpm for 6 h at 4 
°C (IV). After that liposomes were lysed with absolute ethanol and the 
released diclofenac sodium was quantified by HPLC. The percent of 
encapsulation efficiency (EE%) was then calculated according to the 
following equation: 
 
𝐸𝐸% =
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑙𝑖𝑝𝑜𝑠𝑜𝑚𝑒𝑠
𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔
×  100                     (Eq. 8) 
 
 
4.2.5 Drug release studies (I-IV) 
 
Drug release from cation-exchange fibers (I): 
In order to determine apomorphine release from the cation-exchange fibers, the 
drug-loaded fiber bundles were immersed individually (n=3) into 15 ml of extracting 
electrolyte solution (NaCl or CaCl2). The molar amount of extracting electrolyte 
([n+]) was determined on the basis of the molar amount of the compound bound into 
the fiber was equal (1[n+]), ten-fold (10[n+]) or hundred-fold (100[n+]) compared to 
the loaded compound. The release of the bound compound into pure de-ionised 
water was determined as a control. The release profiles were obtained over 24 h by 
sampling 100 µl at 1, 5, 15, 30, 45 min and 1, 2, 4, 8, 12 and 24 h. The release 
experiments were performed at ambient room temperature in amber glass vessels 
placed on a shaker (180 motions/min). 
 
Drug release from nanocarriers (III-IV): 
The drug release studies from drug-loaded FA-PLGA nanoparticles or liposomes 
were carried out in static Franz diffusion cells through MWCO=3.5 kD (III; 
Fisherbrand; Thermo Fisher Scientific, Waltham, MA, USA) or MWCO=6-8 kD 
(IV; Spectra/Por; Spectrum Laboratories, Rancho Dominquez, CA, USA) 
regenerated cellulose dialysis membrane. To mimic physiological conditions, the 
cells were thermostated at 32 °C (III) or 37 °C (IV). Fixed amount of drug-loaded 
nanocarrier dispersion in buffer was placed into the donor compartment. Either 10 
mM (IV) or 25 mM (III) HEPES-buffer containing 154 mM NaCl was used both in 
the donor and receiver compartments. The volume of the receiver compartment was 
5 (IV) or 12 ml (III). 300 µl-sized samples were collected from the receiver 
compartment at 0.5, 1, 2, 3, 4, 6, 8 and 24 h for analysis and replaced with fresh 
buffer. In the study with flufenamic acid loaded-FA-PLGA nanoparticles (III), the 
drug release was also determined under different iontophoretic current profiles: 
100% constant current, 75% on/25% off pulsed current or 50%+:50%- alternating 
current (cathodal, 8h, current density 0.5 mA/cm2, frequency of pulsing 500 Hz). 
 
 
 34 
 
4.2.6 Stability studies (III-IV) 
 
The stability of the drug-loaded nanocarriers was evaluated as a change in 
hydrodynamic diameter and polydispersity index (PDI). The stability under 
iontophoretic current was tracked both for the drug-loaded FA-PLGA nanoparticles 
and liposomes for 8 h under different iontophoretic current profiles (III-IV). 
Following current profiles were used: 100% constant current (III-IV), 75% on/25% 
off pulsed current (III-IV) or 50%+:50%- alternating current (III) (cathodal, current 
density 0.5 mA/cm2, frequency of pulsing 500 Hz). For flufenamic acid-loaded FA-
PLGA nanoparticles, also the stability 1) for 24 h in 25 mM HEPES-buffered saline 
pH=7.4 and 2) for 8 h in contact with human epidermis or porcine full-thickness skin 
were determined (III). The effects of the buffer and iontophoretic current were 
studied in small glass vials. Nanoparticle stability when in contact with human 
epidermis or full-thickness porcine skin was investigated using Franz diffusion cells 
with either the stratum corneum side or the dermal side of the skin membrane facing 
the upper donor compartment containing the nanoparticle dispersion in buffer. 
 
 
4.2.7 Preparation of skin (I-IV) 
 
Human skin was obtained from abdominoplasty patients with the approval of the 
Research Ethic Committee of Saarland in Germany (Ärztekammer des Saarlandes, 
Dec. 2008) (III). Porcine ears were collected from a local abattoir within a few hours 
of post-mortem and were cleaned under cold running water (I-IV). The whole skin 
was removed carefully from the outer region of the ear and separated from the 
underlying cartilage with a scalpel and preserved at -20 °C for further use. Epidermal 
membranes of human (III) or porcine skin (II) were prepared by heat-separation 
technique (Schuetz et al., 2005b): pieces of full-thickness skin were soaked in water 
at 58 °C for 2 min, followed by careful removal of the epidermis from the dermis. 
The epidermis was then washed with water and used in the in vitro studies within 24 
hours. 
 
 
4.2.8 Transdermal in vitro permeation experiments (I-IV) 
 
Side-by-side® diffusion cells (I, II): 
In vitro permeation studies with the drug-loaded cation-exchange fibers were 
performed in Side-by-side®-diffusion cells (Laborexin, Helsinki, Finland). Full-
thickness porcine skin (I) or porcine heat-separated epidermis (II) was clamped 
between two identical halves of diffusion cells. Regenerated cellulose dialysis 
membrane (MWCO=25 kD) was used as a supportive membrane under the 
epidermis (Spectrum Laboratories Inc., Rancho Dominquez, CA, USA). The area of 
exposed skin/epidermis was 0.785 cm2. To mimic physiological conditions, the cells 
were thermostated at 37°C by a surrounding socket. 25 mM HEPES-buffer pH=7.4 
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including 154 mM NaCl was placed in the receiver compartment of the diffusion 
cells. Drug loaded cation-exchange fibers or drug in solution [apomorphine 1 or 5 
mg/ml (I) and leuprorelin acetate 1 mg/ml (II)] was placed into the donor 
compartment. Apomorphine donor solution was prepared in 5 mM citrate buffer 
pH=5, containing 9.51 mM Na+ (I) and leuprorelin acetate donor solution in the 
same buffer as used in the receiver compartment (II). In permeation studies with 
apomorphine, the donor and receiver buffers contained 0.1% of ascorbic acid to 
prevent the auto-oxidative breakdown of the drug (I). As apomorphine and 
leuprorelin acetate are positively charged drugs, they were iontophoresed from the 
anodic compartment. 100 µl- (II) or 300 µl-sized (I) samples were collected for 
analysis from the receiver (in experiments with cation-exchange fibers also from the 
donor) compartment and replaced by fresh buffer at 0.5, 1, 2, 3, 4, 5, 6, 8 (I, II), 12 h 
(II) and 24 h (I, II). 
 
Franz diffusion cells (III, IV): 
In vitro permeation studies with drug-loaded nanocarriers were carried out in static 
Franz diffusion cells. Pieces of human heat-separated epidermis (III) or porcine full-
thickness skin (III, IV) were clamped between the donor and receiver compartments 
of the diffusion cells. Regenerated cellulose dialysis membrane (MWCO=3.5 kD) 
was used as a supportive membrane under the epidermis (Fisherbrand; Thermo 
Fisher Scientific, Waltham, MA, USA). The area of exposed skin/epidermis was 
1.76 cm2 (III) or 0.785 cm2 (IV). To mimic physiological conditions, the cells were 
thermostated at 32 °C (III) or 37 °C (IV). 0.5 ml of drug solution [flufenamic acid 1 
mg/ml (III) and diclofenac sodium 2 mg/ml (IV)] or drug loaded nanocarriers – FA-
PLGA nanoparticles (III) or liposomes (IV) with the equivalent amount of drug in 
buffer – were placed in the donor compartments of the diffusion cells. Either 10 mM 
(IV) or 25 mM (III) HEPES-buffer containing 154 mM NaCl was used both in the 
donor and receiver compartments. The volume of the receiver compartment was 5 
(IV) or 12 ml (III). As flufenamic acid and diclofenac sodium are negatively 
charged at pH=7.4, they were iontophoresed from the cathodic compartment. 300 µl-
sized samples were collected from the receiver compartment at 0.5, 1, 2, 3, 4, 6, 8 
and 24 h for analysis and replaced with fresh buffer.  
 
The effect of cations in donor solution (I): 
In the permeation studies with apomorphine, in addition to the monovalent Na+, the 
effects of divalent Ca2+, trivalent Al3+ as well as of two organic cations with higher 
molecule masses − TEA+ (tetraethylammonium) and BA+ (benzalkonium) − were 
studied. All the salts used were chlorides at a concentration of 154 mM, except for 
benzalkonium chloride (15.4 mM) that possesses surfactant properties and would be 
toxic in such a high concentration. In the experiments with other cations besides Na+, 
no buffering agents were used in the donor solution. 
 
Determination of electroosmotic drug transport (II): 
Acetaminophen is a neutral hydrophilic compound with negligible passive 
permeability (≈2 nmol/ cm2*h) (Schuetz et al., 2005c) and upon the application of 
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iontophoretic current it is driven across the skin predominantly by electroosmosis. 
Hence, in our studies acetaminophen was included in the donor formulation (15 mM) 
to report on the electroosmotic transport from anode to cathode. Electroosmotic 
component of the flux (JEO) was calculated by subtracting the passive flux (JP) from 
the total steady-state flux of acetaminophen (JSS):  
𝐽𝐸𝑂 =  𝐽𝑆𝑆− 𝐽𝑃                                           (Eq. 9) 
 
Assessment of the epidermal integrity (II, III): 
When epidermal sheets were used in permeation experiments, the integrity of the 
membrane was assessed after the experiment using a colorimetric method: 100 µl of 
1% methylene blue solution was added into the donor solution/nanocarrier 
dispersion. The presence of blue coloration in the receptor within 30 min was either 
indicative of defective skin barrier or leakage of test substance as a result of 
improper sealing of the donor and receptor compartments. When the blue coloration 
was observed, the data obtained from that cell was discarded. 
 
Iontophoretic apparatus (I-IV):  
Platinum electrodes were used in all the iontophoretic experiments. During the 
experiments the electrodes were separated from the donor and receiver 
compartments by salt-bridges consisting of 1 M KCl gelled with 2% agarose inside 
silicone tubing (inner diameter 2 mm, length ca. 15 cm). Salt bridges prevented 
direct contact and possible reactions and/or pH-effects of the drug with the 
electrodes. The electrolyte that surrounded the electrodes was 2 M KCl. Current was 
on for 8 h (I, III, IV) or 12 h (II) (Ministat potentiostat, Sycopel Scientific Ltd., 
Boldon, UK), whereafter passive flux was followed up to 24 h. Different current 
profiles – 100% constant direct current (I-IV), 75% on/25% off pulsed current (II-
IV) and 50% on:50% off alternating current (III) – were used in the iontophoretic 
experiments (current density 0.5 mA/cm2, pulsing frequency 500 Hz). For 
determining the relationship between the current density and steady-state flux, 
current densities in the range of 0 - 0.5 mA/cm2 where utilized (I, III). The current 
profiles were adjusted by CFG253 function generator and TDS210 oscilloscope 
(Tektronix Inc., Beaverton, OR, USA) and monitored by Fluke 8808A multimeter 
(Hewlett Packard, WA, USA). 
 
Data analysis (I-IV): 
On the basis of the sample concentrations from the permeation experiments, the 
cumulative amount of drug permeated across the full-thickness skin or epidermis 
was calculated and plotted against time. The linear part of the curve was used for 
calculating the steady-state flux values [(nmol/h*cm2 (I, III, IV) or µg/h*cm2 (II)].  
Iontophoretic enhancement factors were calculated accordingly (I-IV): 
𝐸 =
𝐽𝑖𝑜𝑛𝑡𝑜𝑝ℎ𝑜𝑟𝑒𝑠𝑖𝑠
𝐽𝑝𝑎𝑠𝑠𝑖𝑣𝑒
                   (Eq. 10) 
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where Jiontophoresis and Jpassive are the iontophoretic and passive steady-state flux of the 
drug, respectively. 
Transport numbers were calculated using an equation (I-IV): 
𝑇𝑛 =
𝑧∗𝐹∗𝑑𝑄/𝑑𝑡
𝑀𝑊∗𝐼
                  (Eq. 11) 
where z is the valence of the drug, F is the Faraday`s constant, dQ/dt is the linear 
slope of the iontophoretic phase (in mass units per time), MW is the molecular 
weight and I is the total current passed through the skin. 
 
To determine whether clinically relevant steady-state concentration of a drug in 
the plasma (css, ng/ml) during transdermal delivery could be achieved, css was 
calculated followingly (I-II): 
 
𝑐𝑠𝑠 =
𝐴∗𝐽𝑠𝑠
𝐶𝐿
                     (Eq. 12) 
                  
where A is the surface area for drug absorption, Jss is the steady-state flux, and CL is 
the clearance of the drug from the body. 
 
 
4.2.9 Cryosectioning and imaging (III) 
 
Cryosectioning of the skin was performed immediately after the permeation 
experiments. The surface of the skin was gently cleaned from drug residues with 
deionized water and cotton. Discs of 6 mm in diameter were punched out of skin and 
sections (30 μm thick) were cut at -20°C using a Leica CM3050 cryostat (Leica 
Microsystems, Wetzlar, Germany). On cryosectioning, placement of the skin punch 
was not parallel to the cutting blade of the cryotome to avoid dislocation of the 
particles from outside into the deeper skin layers or vice versa, but in a perpendicular 
position limiting sectioning artefacts (Labouta et al., 2011). The sections were 
mounted in Vectashield Antifade Mounting Medium (Vectorlabs, Burlingame, CA, 
USA) prior to the imaging and observed using confocal laser scanning microscope 
Leica TCS SP5II HCS (Leica Microsystems, Wetzlar, Germany). 
 
 
4.2.10 Analysis of the drugs (I-IV) 
 
HPLC assays (I-IV) 
Apomorphine hydrochloride (I), acetaminophen (II), flufenamic acid (III) and 
diclofenac sodium (IV) concentrations were analysed by high performance liquid 
chromatography (HPLC) instrument by Agilent 1100 Series (Agilent Technologies, 
Germany). The specific parameters are shown in Table 8. 
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Table 8. HPLC parameters for the quantification of the drugs. 
Drug Column Mobile phase Λ (nm) 
Apomorphine HCl 
Gemini NX C18 3 µm 110 Å, 
100 x 4.6 mm  
(Phenomenex Co., USA) 
0.1% TFA pH2.0/ ACN 
(85:15) 
273 
Paracetamol 
Discovery® C18 5 µm,  
150 x 4.6 mm  
(Supelco Analytical, USA) 
0.1% TFA pH2.0/ ACN 
(90:10) 
249 
Flufenamic acid 
LiChrospher 100 RP-18,  
5 µm, 125*4 mm  
(Merck, Germany) 
McIlvaine buffer 
pH2.2/ MeOH (20:80) 
284 
Diclofenac sodium 
Discovery® C18 5 µm,  
150x4.6 mm  
(Supelco Analytical, USA) 
Phosphate buffer 
pH3.0/ MeOH (30:70) 
284 
 
 
UPLC-ESI-MS assays (II): 
For the quantification of leuprorelin acetate concentrations, a method based on ultra-
performance liquid chromatography combined with electrospray ionization mass 
spectrometry (UPLC-ESI-MS) was developed. Chromatographic separation was 
performed with a Waters Acquity UPLC instrument (Waters, MA, USA) and Waters 
Acquity UPLC BEH300 C18 (2.1 x 100 mm, 1.7 µm) column (Waters, MA, USA) at 
50 °C. The mobile phase consisted of 0.01% TFA in deionized water (A) and 0.01 % 
TFA in acetonitrile (B). The gradient elution consisted of 5-100% B at 0-2.5 min, 
100% B at 2.5-3 min, then a reduction to 5% B at 3.1 min; 3.1-5 min, 5% B for 
equilibration of column. The flow-rate was 0.45 ml/min and injection volume 0.1 µl. 
After every sample two blank injections (isopropanol) were made to prevent the 
peptide carryover. The linear concentration range of leuprorelin acetate was 
established in the range of 0.1-50 µg/ml (R2=0.9979). LOQ=0.1 µg/ml, %RSD was 
0.3% and 3% for retention times and peak areas, respectively. Mass spectral 
experiments were carried out using a Xevo triplequadrupole mass spectrometer (TQ-
S) equipped with an ESI source (Waters, MA, USA). The ESI source was operated 
in positive ionization mode. The optimal ESI source parameters were as follows: 
capillary voltage 3.2 kV, cone voltage 26 V, source temperature 150 °C, desolvation 
temperature 500 °C. Nitrogen was used as the desolvation gas (800 L h-1) and cone 
gas (200 L h-1). The multiple reaction monitoring (MRM) mode was employed 
(quantifier 605.47 → 249.10, CE 26 eV and qualifier 605.47 → 110.10, CE 52 eV) 
for quantification. 
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5 RESULTS AND DISCUSSION 
 
5.1 Combined use of ion-exchange fibers and iontophoresis 
for transdermal drug delivery (I-II) 
 
 
5.1.1 Drug binding into cation-exchange fibers (I-II) 
 
The potential of cation-exchange fibers with strong ion-exchange groups (Smopex®-
101, sulphonic acid groups) and weak ion-exchange groups (Smopex®-102, 
carboxylic acid groups) as drug reservoirs in transdermal iontophoresis was tested. 
The properties and scanning electron microscope images of the fibers are presented 
in Table 9 and Figure 6. 
 
Table 9. Characteristics of cation-exchange fibers. 
Cation-exchange 
fiber 
Framework Functional groups 
Binding capacity 
(mmol/g) 
pKa 
 
Smopex®-101 
 
 
polypropylene 
 
S
O
O
O
-
Na
+
 
 
 
4.1 
 
0-1 
 
Smopex®-102 
 
 
polypropylene 
 
O
O
-
Na
+
 
 
 
6.4 
 
3-5 
 
 
 
Fig. 6. Scanning electron microscope images of Smopex®-101 (left) and Smopex®-102 (right) 
cation-exchange fibers. 
 
With both the tested drugs – apomorphine and leuprorelin acetate – similar 
loading was obtained with Smopex®-101 and Smopex®-102 cation-exchange fibers. 
The reason for that may be that too low amounts of the compounds were used for 
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loading, which were not sufficient to bring out the differences in the loading extent. 
For apomorphine (I), no differences in loading efficacy were seen between the two 
fiber types in the case of either 0.1% or 0.25% loading solution (Table 10). Higher 
apomorphine concentration in the loading solution increased the molar amount of 
loading and relative occupancy in both the fibers, but, at the same time, slightly 
decreased the loading efficiency (i.e. % of apomorphine extracted from the loading 
solution). Leuprorelin acetate (II) loading of ≈0.074 mmol per g of fiber was 
obtained with both the cation-exchange fibers, i.e. about 1-2% of the ionic binding 
sites in the fibers were occupied by the peptide. 
 
Table 10. The molar amount (mmol/g) / percentage of loading capacity (%) of apomorphine 
loaded into the cation-exchange fibers after the first and the second loading periods (mean, 
n=10*). Both loading periods were 24 h. 
 * Ten fiber bundles were immersed in the same loading solution.  
 
pH of the loading solution (I-II): 
The pH of the external solution determines the ionization state of both the ion-
exchanger and the drug, and therefore the extent of the ion-exchange process during 
loading or release (Kankkunen et al., 2002a). The ionization degrees of the cation-
exchangers during drug loadings were calculated according to the Henderson–
Hasselbalch equation, I% = 100/[1 + antilog (pKa – pH)].  Apomorphine loading 
solutions were prepared at pH 3.0, at which 99% of the sulphonic acid groups of the 
Smopex®-101 (pKa<1) and only 9.09% of the carboxylic acid groups of Smopex
®-
102 (pKa≈4) were ionized (I) (Florence and Attwood, 2011). Although the difference 
in the degree of ionization between the two fiber types should result in different 
loading extents, the huge shift in the pH of loading solution of Smopex®-102 
probably diminished this effect and by the end of the loading all the carboxylic acid 
groups were ionized (I%=100% at pH 8-8.5). Fiber loading with leuprorelin acetate 
was performed at pH 7.4, at which 100% of the cation-exchange groups in both the 
fiber types were ionized (II). 
 
The degradation rate of easily oxidizing drugs like apomorphine (I) is highly 
dependent on the pH of the solution. Therefore, different pH values and antioxidant 
ascorbic acid concentrations were tested to find out the most stable loading solution. 
The amount of intact drug and pH shifts in the loading solution were measured 
during a two week storage test at room temperature. The turn in the color of the 
solution of apomorphine into green or yellow (depending on the vehicle) indicated 
the formation of oxidation product. The best stability and the smallest pH shift were 
observed in the apomorphine solution at pH 3.0 with no antioxidant. The solutions 
 
Conc. of 
loading 
solution 
Smopex®-101 Smopex®-102 
 After I loading  After II loading After I loading After II loading 
0.1% 0.160/ 3.91% 0.325/ 7.94% 0.155/ 2.42% 0.313/ 4.89% 
0.25% 0.413/ 10.06% 0.827/ 20.16% 0.394/ 6.16% 0.796/ 12.43% 
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with Smopex®-101 fibers remained stable during the whole period of the loading and 
no degradation products were detected visually. At the same time the loading 
solutions of Smopex®-102 and the fibers themselves had a strong green colour after 
24 hours of loading and the pH of the solution had risen to 8-8.5.  
 
The pre-treatment of fibers (I): 
The nature of the preloaded counter-ion may affect the binding of drug into the ion-
exchanger (Jaskari et al., 2001). Therefore, the effect of pre-treatment with NaCl or 
HCl on subsequent loading with apomorphine was determined (I). The pre-treatment 
of cation-exchange fibers with NaCl solution did not increase apomorphine loading 
to either fiber type, as all of the ion-exchange groups had been already occupied with 
sodium ions prior to that. At the same time, when the fiber bundles were pre-treated 
with HCl (especially in the case of Smopex®-102), the amount of  drug loaded into 
the fibers was also changed (Fig. 7), together with improvement in drug stability 
during the loading procedure. In the case of Smopex®-101, the acid pre-treatment 
slightly increased the loading degree. On the contrary, an enormous decrease in 
loading was seen after the Smopex®-102 fibers were pre-treated with HCl. It seemed 
that in Smopex®-102 fibers, H+ ions in the HCl solution were quickly exchanged 
with Na+-ions. Later during the loading of drug, the exchange between H+ and 
apomorphine+-ions in the fiber seemed to be very slow and only a small fraction of 
apomorphine was bound to Smopex®-102 during the 48 hour loading period. 
 
 
 
Fig. 7. The molar amount (mmol/g) of apomorphine bound to cation-exchange fibers without 
(101-Na and 102-Na) or with (101-H and 102-H) 100 mM HCl pre-treatment (mean ± SEM, n=3). 
 
In summary, the extent of drug loading and the stability were dependent on the 
ion-exchange groups of the fiber, the preloaded counter-ions attached to the ion-
exchange groups and pH of the loading solution. 
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5.1.2 Drug release from ion-exchange fibers (I) 
 
The effect of counter-ion concentration and valence: 
The interchange of drug bound to the cation-exchange fibers and the counter-ions of 
the external solution is dependent on the electrical potential difference (Donnan 
potential) between the two phases (Helfferich, 1995). Increase in the concentration 
of counter-ions in the solution (i.e. the ionic strength) or in the valence of counter-
ion leads to a decrease in the Donnan potential (Hänninen et al., 2007; Jaskari et al., 
2001; Kankkunen et al., 2002a). Lower Donnan potential means that the interaction 
between the drug and the ion-exchange groups is weaker, allowing more extensive 
release of the drug from the fiber. The rate and extent of the release of apomorphine 
was clearly higher when the concentration of the counter-ion in the surrounding 
solution was increased (Fig. 8). Also, at equimolar amounts, divalent Ca2+ was more 
efficient in releasing apomorphine from both the cation-exchange fibers than 
monovalent Na+. In addition to reduced Donnan potential, significantly higher 
charge density of Ca2+ compared to Na+ contributed to the process. 
 
 
 
Fig. 8.  The release profiles of apomorphine from Smopex®-101 (A and C) and Smopex®-102 (B 
and D) cation-exchange fiber bundles during 24 h (mean ± SEM, n=3). The molar amount of 
extracting sodium- (closed symbols) or calcium-ions (open symbols) in the release media was 
equal (1[n+]), 10 fold (10[n+]) or 100 fold (100[n+]) compared to the loaded apomorphine amount. 
 
The effect of the cation-exchange groups: 
The studied cation-exchange fibers share the same polymeric framework – 
polypropylene – but different cation-exchange groups (sulphonic or carboxylic acid 
in Smopex®-101 or Smopex®-102, respectively). The results demonstrated that more 
apomorphine was released from the fiber with weak carboxylic acid groups than 
from the fiber with strong sulphonic acid groups (Fig. 8). Different release profiles 
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between the fiber types were seen only when using CaCl2 as the extracting 
electrolyte. In the case of Smopex®-102, the strongest extracting solution used 
(100[n+] CaCl2) released about 30% of bound apomorphine during 24 h, while from 
Smopex®-101 fibers the corresponding value did not exceed 15%. Since the specific 
interactions between apomorphine and the fibers seemed to be strong, the release 
from the fibers remained quite low at all the electrolyte concentrations. Thus, 
apomorphine acted similarly to other lipophilic drugs, such as propranolol or tacrine, 
that are bound more strongly to the strong sulphonic acid groups than to the weaker 
carboxylic acid groups (Jaskari et al., 2001; Vuorio et al., 2003). The different 
impact of Ca+2 on the cationic drug release between the fibers with sulphonic acid or 
carboxylic acid groups has been claimed to be due to the strong binding of Ca+2 to 
the carboxylic groups (Charman et al., 1991). 
 
In conclusion, the drug release from the cation-exchange fibers could be 
controlled by modifying either the fiber type or the ionic composition of the external 
solution. 
 
 
5.1.3 Drug permeation from solution formulations (I-II) 
 
Apomorphine permeation (I): 
Apomorphine permeation experiments were conducted with donor solutions at pH5 
due to an increase in the rate of degradation of the drug at higher pH values. The 
application of the iontophoresis significantly enhanced the in vitro permeation of 
apomorphine across the full-thickness porcine skin (Fig. 9A and Table 11). A 
steady-state flux was attained in all protocols after approximately three hours and the 
lag-time for the highest current density (0.5 mA/cm2, 5 mg/ml donor solution) was 
134 minutes. 
 
 
 
Fig. 9. A. The cumulative amount of apomorphine (µg/cm2) permeated into the receiver 
compartment across the porcine skin passively and at different current densities. B. Relationship 
between current density and steady-state flux of apomorphine. The donor solution contained 5 
mg/ml of apomorphine. The current was on for 8 h, whereafter passive drug permeation was 
followed for up to 24 h. Mean ± SEM, n=3-5. 
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Integrity of the skin and reversibility of the permeability increase were tested by 
measuring the passive flux after switching off the current at 8 h. The post-
iontophoretic flux remained at a higher level compared to the normal passive flux of 
apomorphine. The relationship between the current density and steady state flux was 
determined at 5 mg/ml apomorphine donor solution concentration and at a current 
density range of 0-0.5 mA/cm2 (Figure 9B). A linear relationship (r2=0.9007) 
between these two parameters was established.  
 
Table 11. Passive and iontophoretic fluxes (Jss) and enhancement factors (E) of apomorphine 
across porcine skin from donor solutions at two different drug concentrations. Mean ± SEM. n=3-
5. 
 
 Therapeutic plasma levels of apomorphine range between 1.4-10.7 ng/ml (Neef 
and van Laar, 1999) and CL = 40.4 ± 15 ml/min/kg (van der Geest et al., 1998). 
Assuming a direct correlation between the in vitro and in vivo permeation and 
utilizing an Eq. 12 (Page 37), steady-state plasma concentrations css was calculated. 
Iontophoretic delivery from the 5 mg/ml solution at the maximum current density 
from a 25 cm2-sized permeation area (typical size of the patch) would result in a 
plasma level of 4.41 ng/ml of apomorphine. Thus, transdermal iontophoretic delivery 
of apomorphine can be therapeutically significant at our experimental parameters.  
 
Leuprorelin permeation (II): 
The permeation experiments with leuprorelin acetate (Fig. 10 and Table 12) were 
conducted with donor solutions at pH 7.4, where the peptide possesses a net charge 
≈+1 (Hoogstraate et al., 1994). This pH was utilized as it has been proposed that the 
iontophoretic delivery of monovalent leuprorelin (at pH 7-8) is more efficient 
compared to divalent leuprorelin (at pH 4.5-5), as the divalent ions migrate slowly 
and may interact more with the charged sites in the skin (Lu et al., 1993). Passive 
permeability values were in agreement with those reported earlier (Kochhar and 
Imanidis, 2003, 2004) and rather small due to the large molecular weight and charge 
of the compound. The application of the iontophoresis significantly enhanced the in 
vitro delivery of the peptide across the porcine epidermis. 
 
The pulsed current (PC) was slightly more efficient in carrying leuprorelin across 
the epidermis than constant current. Although, the results failed to show statistical 
difference by unpaired t-test, about 15% increase in the mean value of steady-state 
flux and about 22% increase in the cumulative amount of peptide delivered during 
12 h of iontophoretic treatment were obtained with the pulsed current compared to 
100% constant direct current. The total amount of current passed through the 
Current density 
(mA/cm²) 
1 mg/ml 5 mg/ml 
Jss 
(nmol/h*cm2) 
E 
Jss 
(nmol/h*cm2) 
E 
0 0.47 ± 0.23 1 1.50 ± 0.13 1 
0.20 20.41 ± 1.92 43 43.36 ± 3.72 29 
0.35 - - 74.11 ± 10.73 50 
0.50 50.93 ± 6.50 108 95.64 ± 4.17 64 
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epidermis in pulsed current profile was 25% smaller than in 100% DC profile. When 
normalizing 75% PC flux values to the same current amount as in 100% of DC 
profile, the transport of the peptide would be far more effective (≈50% increase in 
effective flux and ≈60% increase in amount of peptide delivered in 12 h). 
Furthermore, when comparing the transport numbers of the two iontophoretic current 
treatments by unpaired t-test, a statistically higher value was obtained with the 
pulsed current compared to constant current. 
 
 
 
Fig. 10. The cumulative amount of leuprorelin (µg/cm2) permeated into the receiver compartment 
across the porcine epidermis passively (0 mA/cm2) and with the 100% constant (0.5 
mA/cm2 100% DC) and 75%on:25%off pulsed current (0.5 mA/cm2 75% PC). Mean ± SD, n=5-6. 
 
After iontophoretic current termination, leuprorelin acetate amounts in the 
receiver compartment of the diffusion cells decreased rapidly, most probably due to 
the adsorption of the peptide onto skin. Although the proteolytic activity of skin is 
much lower compared to mucosal routes (Steinstrasser and Merkle, 1995), we also 
cannot fully exclude the possibility of degradation of the peptide during the 
permeation experiments, as metabolism during transdermal delivery has been 
reported for a number of LHRH analogues (Delgado-Charro and Guy, 1995; Miller 
et al., 1990). The donor solution peptide concentrations were stable when kept at 
37°C for 24 h 
 
Table 12. Steady-state fluxes (Jss), cumulative amounts (Q) of peptide delivered in 12 h, transport 
numbers (Tn) and iontophoretic enhancement factors (E) of leuprorelin delivered passively or by 
different iontophoretic current profiles. Mean ± SD. n=4-6.  
ns not significant (p>0.05) Jss and Q 75% PC vs 100% DC; ** p<0.01 Tn 75% PC vs 100% DC 
(unpaired t-test). 
 
 
 
Current profile J
ss
 (µg/h*cm
2
)  
 
Q in 12 h 
(µg/cm²) 
 
Tn E 
0 mA/cm²     0.47 ± 0.286 6.54 ± 2.063 - - 
100% DC 3.81 ± 0.820 35.26 ± 13.900 1.70 x 10-4 ± 3.64 x 10-5 8.1 
75% PC     4.36 ± 0.758ns  43.07 ± 9.407ns 2.59 x 10-4 ± 4.45 x 10-5** 9.3 
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5.1.4 Electroosmotic transport of leuprorelin (II) 
 
In order to estimate the magnitude of electroosmotic transport of the peptidic drug 
leuprorelin, a neutral polar molecule acetaminophen was included into the donor 
formulations. Transdermal transport of neutral molecule during anodal iontophoresis 
is mainly driven by electroosmosis (plus passive diffusion) and, hence, it gives a 
good estimation about the changes in the contribution of the electroosmosis as a 
transport mechanism for the molecule of interest (Fig. 11). Surprisingly, in the 
presence of the peptide in the donor formulation, the passive but not the 
iontophoretic flux of the marker compound was hindered during the 100% constant 
current treatment (p<0.05 by unpaired t-test). As the electroosmotic flux of 
compound is directly related to the amount of current passed across the epidermis, 
the pulsed current profile resulted in lower acetaminophen flux compared to the 
constant current profile when acetaminophen was iontophoresed alone. About 20% 
decrease was observed both in steady-state flux and amount of the marker compound 
permeated in 12 h with 75%on:25%off pulsed current treatment. Curiously, in the 
presence of leuprorelin in the donor formulation, the pulsed current treatment 
slightly increased the total acetaminophen flux compared to the constant current 
treatment although the results failed to demonstrate the statistical difference because 
of high variation.  
 
 
 
Fig. 11. Cumulative amounts of electroosmotic marker acetaminophen delivered across porcine 
epidermis during 12 h passively and with iontophoresis with (w LEU) and without (wo LEU) 
leuprorelin acetate at 100% constant (100% DC) and 75%on:25%off pulsed current (75% PC). 
Mean ± SD, * p˂0.05 passive wo LEU vs passive w LEU (unpaired t-test). 
 
Naturally, several assumptions are prerequisites to such analysis (Schuetz et al., 
2005a). Firstly, the marker and the drug should be transported in a similar fashion by 
convective solvent flow. Secondly, there should be no interaction between these two 
substances. And thirdly, the electroosmotic flux of the marker should be proportional 
to its donor concentration. 
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The fractions of both transport mechanisms involved in acetaminophen delivery − 
passive diffusion and electroosmosis – from its total flux under constant and pulsed 
iontophoretic delivery − have been demonstrated in Fig 12. Electroosmotic 
component of the flux (JEO) has been calculated according to the Eq. 9 (Page 36). To 
eliminate the differences in flux values due to the amount of current delivered, 
electroosmotic fluxes obtained with 75%on:25% off pulsed current (75% of the time 
the current was on) have been normalized to the total amount of current delivered 
during the 12 h of constant current treatment at the current density of 0.5 mA/cm2 
(100% of the time the current was on). Under constant current, the presence of the 
peptide had no effect on the total flux of acetaminophen. As the passive transport of 
the compound was inhibited, we believe that higher electroosmotic transport 
compensated for that part, so that the total flux remained the same as without the 
peptide in donor solution. The situation under pulsed current was different. As in the 
presence of the peptide, the total flux of acetaminophen was significantly higher than 
without the peptide, we suggest that this change was caused by the combined effects 
of enhanced electroosmotic transport and reduced inhibition of passive diffusion.  
 
 
 
Fig. 12. The estimated proportions of diffusion (D) and electroosmosis (EO) from the total flux of 
acetaminophen delivered without (wo) and with (w) leuprorelin acetate. Electroosmotic flux 
values from 75% PC iontophoresis have been normalized to the total amount of current delivered 
at 100% DC treatment. Mean ± SD. * p<0.05 100% DC EO and 75% PC EO wo LEU vs w LEU; 
** p<0.01 100% DC D wo LEU vs w LEU and D w LEU 100% DC vs 75% PC. 
 
Based on these results we can conclude that pulsed current may offer significant 
benefits over constant current in the transdermal iontophoretic delivery of 
therapeutic peptides that have a tendency to adsorb into the skin and inhibit 
electroosmosis as their main transport mechanism. The significantly higher transport 
number obtained by the pulsed current demonstrated improved transport efficiency 
due to the more pronounced electroosmotic solvent flow.  
 
 
5.1.5 Drug permeation from ion-exchange fibers (I-II) 
 
Transdermal in vitro permeation of leuprorelin (II) was investigated from both of the 
cation-exchange fibers − Smopex®-101 and Smopex®-102 (Fig. 14), while only 
Smopex®-101 cation-exchange fibers were chosen as drug reservoirs for 
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apomorphine (I), as degradation of the drug was observed when it was loaded into 
Smopex®-102 fibers (Fig. 13). When the cation-exchange fibers loaded with either 
apomorphine or leuprorelin were used in the donor compartment of the diffusion 
cells, a gradual drug release from the fibers was observed during the application 
period of iontophoresis and then the concentration in the donor compartment 
remained almost constant. Different release profiles of leuprorelin were observed 
from the Smopex®-101 and Smopex®-102 fibers (II). From Smopex®-101 fibers that 
possess stronger sulphonic acid as the ion-exchange groups, the release remained 
slower and more limited compared to Smopex®-102 fibers with weaker carboxylic 
acid as ion-exchange groups. In general, as only a small fraction of the total drug 
inside the fibers was released during the 24 h of the permeation studies, the drug 
fluxes from the fibers remained lower compared to those from drug solutions (I-II; 
Table 13 and 14).  
 
 
Fig. 13. The amounts of apomorphine in the donor and receiver compartments during 
iontophoretic delivery (0.5 mA/cm2) across the porcine skin from Smopex-101 ion-exchange fiber 
(containing 24.66 ± 0.26 mg of apomorphine). The current was on for 8 h (mean ± SEM. n=6). 
 
 
Table 13. Apomorphine release from Smopex®-101 ion-exchange fibers and passive and 
iontophoretic fluxes (Jss) across porcine skin (mean ± SEM, n=6).  
 
Despite of significantly lower fluxes from the cation-exchange fibers (compared 
to peptide flux from solution), one must take into account that leuprorelin acetate is a 
very potent drug (II). Taking into account the plasma clearance of the peptide 
(Sennello et al., 1986), a continuous delivery rate of 8.4 µg/h for 24 h has been 
calculated to be necessary for therapeutic effect (Kochhar and Imanidis, 2004). With 
the steady-state fluxes obtained from Smopex®-101 and Smopex®-102 fibers, 27.1 
cm2 and 12 cm2 permeation areas were calculated as sufficient to achieve 
therapeutically effective delivery rate of leuprorelin, respectively. So the delivery of 
LHRH analogue leuprorelin acetate is feasible in therapeutic amounts from a drug 
reservoir based on cation-exchange fibers. 
Current density  
(mA/cm²)  
Amount of drug 
released in 24 h (%)  
J
ss
 (nmol/h*cm
2
)  
0  1.7  0.07 ± 0.01 
0.20  2.2  0.95 ± 0.09  
0.50  2.0  4.30 ± 0.32  
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Fig. 14. The cumulative amounts of leuprorelin acetate in the donor and receiver compartments 
during 12 h iontophoretic delivery (0.5 mA/cm2 constant current) across the porcine epidermis 
from Smopex®-101 (A and B) Smopex®-102 (C and D) ion-exchange fibers (containing 9.12 and 
8.91 mg of peptide, respectively). Mean ± SD, n=4. 
 
 
Table 14. The release of leuprorelin acetate from Smopex®-101 and Smopex®-102 cation-
exchange fibers and iontophoretic fluxes (Jss) across porcine epidermis (mean ± SD, n=4).  
 
 
 
5.1.6 The effect of cations in the donor solution (I) 
 
In experiments with apomorphine-loaded Smopex®-101 fibers, the impact of the 
cation (Na+) concentration and nature of the cation were investigated (Table 15). In 
addition to the monovalent Na+, the effect of divalent Ca2+, trivalent Al3+ as well as 
of two organic cations with higher molecule masses − TEA+ (tetraethylammonium) 
and BA+ (benzalkonium) − were studied. As the iontophoretic mobility of a 
compound is inversely related to its molecular weight (Yoshida and Roberts, 1993), 
TEA+ and BA+ carry less current due to their lower mobility. Cations other than Na+ 
were all used as chloride salts at a concentration of 154 mM, except for 
benzalkonium chloride (15.4 mM) that possesses surfactant properties and would be 
toxic at such a high concentration. Results from these experiments demonstrated that 
both the Na+ concentration and the cation type in the donor solution exerted 
statistically significant effects on transdermal steady-state flux of apomorphine 
(p<0.001). 
Fiber  
Amount of peptide 
released in 12 h (%)  
J
ss
 (µg/h*cm
2
)  
Smopex®-101 5.1 ± 0.6 0.31 ± 0.18 
Smopex®-102 12.9 ± 6.0 0.71 ± 0.28  
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Table 15. The effect of Na+ concentration and different cations in the donor buffer on the release 
and iontophoretic flux (Jss) of apomorphine at a current of 0.5 mA/cm2 (mean ± SEM. n=6).  
** p < 0.01 15.4 mM BA+ vs 154 mM Na+; *** p < 0.001 1540 mM Na+, 154 mM Ca2+ and 154 mM 
Al3+ vs 154 mM Na+ (One-way ANOVA following Bonferroni`s multiple comparison test). 
The concentration of cation: 
When using a 1540 mM Na+ in the donor buffer, the release of the drug was 
improved compared to that of 154 mM Na+, but the flux across the skin remained 
significantly lower. At the same time, when 15.4 mM Na+ was used in the donor, the 
flux was increased, despite of the smaller release of the drug from the fibers. On one 
hand, higher concentration of Na+ would result in a decrease in Donnan potential 
leading to more extensive drug release from the ion-exchanger. At the same time it 
means more competition for the drug in the iontophoretic flux because of the 
presence of higher amounts of smaller and more mobile cations. Also, higher salt 
concentration in the donor formulations creates a water gradient over skin and thus, 
less hydrated tissue that could result in decreased transdermal drug fluxes (Bjorklund 
et al., 2010). Therefore, aiming for the highest fluxes possible, the amount of 
competing co-ions should be kept as low as possible as it affects the iontophoretic 
flux more than the actual drug concentration in the donor compartment. As expected, 
the 15.4 mM Na+ provided also the highest transport number for the drug as the 
presence of competitive ions was the smallest.  
 
The nature of cation: 
As expected, the multivalent cations released more apomorphine from the cation-
exchange fibers compared to Na+ at the same molar concentration, and the release 
was increased with the increasing cation valence. At the same time, the iontophoretic 
transdermal fluxes of apomorphine from these donor solutions remained very low. 
The reason for that is the higher competition for the drug in the iontophoretic flux as 
cations with higher valence also carry higher fraction of the total current. Also, as 
the pH of the solutions of these chlorides (CaCl2 and AlCl3) was below the 
isoelectric point of the porcine skin, the negative charge of the skin was reversed and 
the cation transport suppressed. The solutions of organic cations released more 
apomorphine from the fibers compared to 154 mM Na+, but at the same time, no 
Cation in the 
donor 
pH of 
donor 
Amount of 
drug released 
in 24 h (%) 
J
ss
 
(nmol/h*cm
2
) 
Tn 
15.4 mM Na+ 5.00 0.9 6.09 ± 0.80 3.26 x 10-4 ± 4.27 x 10-5 
154 mM Na+ 5.00 2.0 4.30 ± 0.32 2.30 x 10-4 ± 1.70 x 10-5 
1540 mM Na+ 5.00 3.8 0.56 ± 0.08 *** 0.30 x 10-4  ± 0.43 x 10-5 
154 mM Ca2+ 3.18 5.8 1.23 ± 0.01 *** 0.66 x 10-4  ± 0.06 x 10-5 
154 mM Al3+ 2.94 7.5 0.21 ± 0.09 *** 0.11 x 10-4  ± 0.46 x 10-5 
154 mM TEA+ 5.00 3.6 4.79 ± 0.49 2.57 x 10-4  ± 2.65 x 10-5 
15.4 mM BA+ 5.00 3.7 2.15 ± 0.29 ** 1.15 x 10-4  ± 1.58 x 10-5 
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improvement in transdermal flux was observed. Overall, the amount of drug released 
into the donor compartment and the corresponding transdermal steady-state flux of 
apomorphine did not correlate to each other when different cations were used in the 
donor compartment.  
 
In summary, cation-exchange fibers can be regarded as suitable reservoir 
materials to be combined with iontophoresis in order to retard the release of small or 
large molecular therapeutics and to provide additional control in their transport 
across the skin. By a suitable choice of the ionic composition of the donor 
formulation the release and flux kinetics can me modified to meet the required 
needs. 
 
 
5.2 Combined use of nanocarriers and iontophoresis for 
transdermal drug delivery (III-IV) 
 
5.2.1 Properties of the nanocarriers (III-IV) 
 
In this part of the study, we aimed at producing drug-loaded nanocarriers (polymeric 
nanoparticles and liposomes) possessing a surface charge of the same sign as the 
drug loaded inside the carriers. Thereby, the benefit from the iontophoretic treatment 
to the transdermal drug delivery would be two-fold. According to our hypothesis, 
firstly, the electric current would push the liposomes into hair follicles, that has been 
recognized as one of the possible routes in transdermal absorption of drugs (Lauer et 
al., 1995). Thereafter, iontophoresis would pump the drug released from the depot in 
the skin or on the surface of the skin further into the bloodstream.  
 
FA-PLGA nanoparticles (III): 
Hydrophobic model drug – flufenamic acid (FFA) − was loaded into FA-PLGA 
nanoparticles (Fig. 15). The properties of the prepared drug-loaded and respective 
drug free FA-PLGA nanoparticles are presented in Table 16. 
 
 
Fig. 15. Scanning electron microscope image of flufenamic acid-loaded FA-PLGA nanoparticles. 
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Table 16. Properties of flufenamic acid-loaded and respective drug-free FA-PLGA nanoparticles 
(mean ± SD, n=3). 
 
 FFA loaded particles Blank particles 
Mean diameter (nm) 174.2 ± 1.8 179.0 ± 2.6 
PDI    0.074 ± 0.004 0.072 ± 0.026 
Zeta-potential (mV) -8.50 ± 0.14 -17.80 ± 0.20 
Drug content (w/w%)* 5.6 ± 0.2 - 
        * Grams of FFA in 100 g of lyophilized nanoparticles 
Liposomes (IV): 
Four different types of liposomes (conventional, pegylated, ultradeformable and 
ethosomes) were prepared and loaded with a hydrophilic model drug – diclofenac 
sodium (DS) (compositions are found in Table 7 in Section 4.2.3). The properties of 
the developed drug-loaded lipid vehicles are summarized in Table 17. 
 
Table 17. Particle size, polydispersity index (PDI), charge (zeta potential) and mean 
encapsulation efficiency (EE%) of the prepared DS lipid vesicles. 
 
Formulation and code Size (nm) PDI Charge (mV) Mean EE% 
Conventional liposomes (F1)  147.0 ± 1.5 0.085 ± 0.013 -34.3 ± 1.7 
 
67.5 
 
Pegylated liposomes (F2) 144.2 ± 0.1 0.079 ± 0.029 -27.7 ± 1.0 60.4 
Transfersomes (F3) 117.7 ± 0.5 0.073 ± 0.028 -29.8 ± 1.6 79.9 
Ethosomes (F4) 116.5 ± 0.6 0.104 ± 0.005 -26.7 ±1.9 49.6 
 
 
5.2.2 Stability of the nanocarriers  
 
Prior to the permeation experiments, the electrochemical stabilities of the drug-
loaded nanocarriers were evaluated under different iontophoretic current modes (III-
IV). The stability of the FFA-loaded FA-PLGA nanoparticles was also determined 
when in contact with human epidermis or porcine full-thickness skin (III). All the 
results are presented as a change in hydrodynamic diameter and polydispersity index 
(PDI). 
 
With the FFA-loaded FA-PLGA nanoparticles (III), no changes in hydrodynamic 
diameter or PDI were detected during the 72 h incubation of the particles in buffer 
without iontophoretic current or during the 8 h under constant, pulsed or alternating 
current (Fig. 16). At the same time, a significant increases both in hydrodynamic 
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diameter and PDI were observed after the FFA-loaded FA-PLGA nanoparticles had 
been in contact with the lower (dermal) side of human epidermis and full-thickness 
porcine skin for 24 h. This was not evident when the nanoparticle dispersion was 
placed on the upper (stratum corneum) side of the skin. Most likely the reason for 
such results was the separation/diffusion of skin components into the nanoparticle 
dispersion (and/or subsequent aggregation of the particles) during incubation. The 
degradation of the nanospheres is highly unlikely considering that short incubation 
times and fresh formulations were always used (Wu and Wang, 2001).  
 
 
 
Fig. 16. Stability of FFA FA-PLGA nanoparticles expressed as a change in hydrodynamic 
diameter and PDI in 25 mM Hepes buffered saline pH=7.4 for 72 h (A), under different 
iontophoretic current profiles for 8 h (B) and in contact with stratum corneum (SC) or dermal side 
of human epidermis (C) or full-thickness porcine skin for 24 (D). Mean ± SD, n=3; * p < 0.05, ** p 
< 0.01, *** p < 0.001 (One-way ANOVA following Bonferroni`s multiple comparison test). 
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With liposomes (IV), no changes in hydrodynamic diameters were detected after 
8 h of incubation of any vesicle formulation under constant or pulsed current (Fig. 
17). The PDIs of formulations F1, F2 and F3 had increased slightly, but these 
changes did not reach statistical significance (p>0.05 when compared with unpaired 
t-test before and after current treatment). Although pore widening of lipid bilayers 
under electric field has been associated with breakdown of liposomes and leakage of 
loaded drug, the magnitude of current used in typical transdermal iontophoretic 
treatment regimens is too small to cause such rupture of vesicles. Furthermore, under 
electric current field the fusion of charged vesicles is inhibited, so it can contribute to 
better colloidal stability of the study formulations.  
 
 
 
Fig. 17. Electrochemical stability of liposomes under iontophoretic current for 8 h expressed as a 
change in hydrodynamic diameter and PDI. Mean ± SD, n=3. 
 
 
5.2.3 Drug release from nanocarriers  
 
The drug formulation to be utilized in combination with transdermal iontophoresis 
should preferably avoid immediate/burst drug release and deliver the drug to the 
permeation site in a gradual yet continuous manner. In this way, more predictable 
and controlled drug transport could be achieved, resulting in transdermal drug 
transport less dependent on skin variables. The release kinetics of drugs from the 
nanocarriers was studied in a similar setting as the in vitro transdermal permeation 
tests – at 32 °C (III) or 37°C (IV) in static Franz diffusion cells, using a synthetic 
dialysis membrane to separate the donor compartment from the receiver 
compartment. From FA-PLGA nanoparticles the drug release was also determined 
under different iontophoretic current modes (III).  
 
In experiments with FFA-loaded PLGA nanoparticles, the amount of FFA 
gradually increased in the receiver compartment upto 8 h, followed by a plateau at 
≈50% of encapsulated drug amount released (Fig. 18). The application of 
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iontophoretic current – constant, pulsed or alternating – did not have any effect on 
the release of FFA from the nanoparticles. This result is supported by an earlier 
study where the release of peptidic drug triptorelin from PLGA nanospheres was 
also found not to be affected by iontophoretic current (Nicoli et al., 2001).  
 
 
 
Fig. 18. Release of FFA from FA-PLGA nanoparticles passively and under different current 
modes. Current was on for 8 h. The total amount of FFA in nanoparticles was 50 µg. Mean ± SD, 
n=3). 
 
From all the liposome formulations DS was released at a similar rate, resulting in 
≈50% of the encapsulated drug released in 24 h (Fig. 19). In general, the most 
important factors affecting drug release from liposomes are the physicochemical 
properties of the liposome membrane and the therapeutic agent, and the vesicle size 
(Lindner and Hossann, 2010). All our formulations possessed similar vesicle size 
and drug-to-lipid ratio (data not shown) and the effects of differences in composition 
(inclusion of surfactant, ethanol or cholesterol) on release were not evident in this 
study. Thus, all the formulations demonstrated suitable release kinetics to be used in 
transdermal delivery purposes and any changes in transport efficiency of DS from 
different lippid vesicle formulations across the skin could only be attributed to the 
differences in liposome-skin-iontophoretic current interactions − not in drug release 
rate. 
 
Fig. 19. Release of diclofenac sodium (DS) from different liposome formulations (F1-F4). The 
total amount of DS in liposomes was 100 µg. Mean ± SD, n=3. 
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In summary, all the prepared nanocarriers were deemed suitable for transdermal 
iontophoretic administration, regarding the colloidal properties, stability under 
iontophoretic current and release kinetics. 
 
 
5.2.4 Drug permeation from solution  
 
Permeation studies with flufenamic acid (FFA; III; Fig. 20 and Table 18) and 
diclofenac sodium (DS; IV; Fig. 21 and Table 19) were conducted at pH 7.4, where 
they carry a negative charge and can therefore be administered under a negatively 
charged electrode (cathode). According to the Henderson–Hasselbalch equation, at 
pH 7.4 practically all FFA and DS are ionized state (99.97% and 99.94% for FFA 
and DS, respectively) and can therefore maximally benefit from the iontophoretic 
current. As is evident from experiments with drug solutions, the application of 
iontophoresis significantly increased the permeation of both the drugs across the 
skin. As the iontophoretic flux of compounds is typically directly related to the 
amount of current passed through the skin, the constant current was the most 
effective protocol in enhancing the in vitro transdermal delivery of FFA and DS (III-
IV). As expected, the pulsed current profile resulted in ≈25% lower steady-state flux 
values compared to the constant current as the current was on only 75% of the time. 
The application of alternating current was quite inefficient in transporting negatively 
charged FFA across the skin and the steady-state flux values remained only slightly 
superior to passive delivery (III).  
 
 
 
Fig. 20. The permeation curves of FFA without (passive) and with different iontophoretic current 
modes across human epidermis from solution (A) and FA-PLGA nanoparticulate formulation (B) 
and across porcine full-thickness skin from solution (C) and FA-PLGA nanoparticulate formulation 
(D). 100 % DC – constant direct current 0.5 mA/cm2; 75% PC – 75% on:25% off pulsed current; 
50%:50% AC – 50% cathodal:50% anodal alternating current (mean ± SD, n=4-6). 
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For FFA, a linear relationship with r2= 0.8241 between the current density and 
steady-state flux values was established in experiments with human epidermis as a 
permeation membrane at a donor concentration of 1 mg/ml of FFA over a constant 
current density range of 0 - 0.5 mA/cm2 (III). Therefore, increasing the current 
density of the donor solution resulted in higher steady-state fluxes.  
 
 
Table 18. The descriptive values calculated from FFA permeation curves (mean ± SD, n=4-7).  
Current type 
Jss a 
(nmol/h*cm2) 
E b Q8h (µg) c Tn d 
H
u
m
a
n
 e
p
id
e
rm
is
 
FFA solution 
Passive 9.29 ± 1.67 - 30.0 ± 4.6 - 
100% DC 33.56 ± 5.72 3.8 101.6 ± 30.4 1.79 x 10-3 ± 3.06 x 10-4 
75% PC 25.73 ± 6.95 2.8 93.2 ± 23.4 1.84 x 10-3 ± 4.96 x 10-4 
50%:50% AC 11.06 ± 2.76 1.2 59.5 ± 27.2 0.87 x 10-3 ± 4.92 x 10-4 
FFA FA-PLGA nanoparticles 
Passive 3.07 ± 1.39 - 10.5 ± 4.9 - 
100% DC 11.59 ± 2.11 3.8 39.9 ± 6.3 6.21 x 10-4 ± 1.13 x 10-5 
75% PC 15.13 ± 13.86 ns 4.9 54.1 ± 12.62 * 9.41 x 10-4 ± 3.68 x 10-4 ns 
50%:50% AC 5.02 ± 0.33 1.6 18.0 ±4.1 2.69 x 10-4 ± 4.32 x 10-5 
P
o
rc
in
e
 s
k
in
 
FFA solution 
Passive 4.37 ± 1.73 - 20.9 ± 7.7 - 
100% DC 12.75 ± 3.57 2.9 58.5 ± 15.6 1.66 x 10-3 ± 7.43 x 10-4  
75% PC 10.21 ± 3.73 2.3 47.7 ± 16.3 7.29 x 10-4 ± 2.67 x 10-4 
50%:50% AC 6.67 ± 3.43 1.5 30.7 ±15.6 3.57 x 10-4 ± 1.84 x 10-4  
FFA FA-PLGA nanoparticles 
Passive 1.28 ± 0.65 - 7.1 ± 2.8 - 
100% DC 2.76 ± 1.14 2.2 13.4 ± 5.1 1.48 x 10-4 ± 6.09 x 10-5 
75% PC 2.46 ± 0.76 1.9 11.2 ± 4.9 1.62 x 10-4 ± 7.02 x 10-5 
50%:50% AC 1.77 ± 0.21 1.4 8.8 ± 0.7 9.46 x 10-5  ± 1.13 x 10-5 
a steady-state flux; b enhancement factor; c cumulative amount of drug permeated in 8h; d 
transport numbers. ns not significant (p>0.05) Jss and Tn 75% PC vs 100% DC; * p<0.05 Q8h 75% 
PC vs 100% DC (unpaired t-test).  
 
 
5.2.5 Drug permeation from nanocarriers  
 
In general, the use of nanocarrier formulations in the donor compartments of 
diffusion cells resulted in decreased steady-state flux values and increased lag-times 
compared to the FFA (III) or DS (IV) delivery from solutions. This was caused by 
the gradual and limited release of the model compound from the nanoparticles or 
liposomes during the time frame of permeation experiments. It is possible that this 
incubation time was too short to demonstrate the potential superiority of 
nanoencapsulation of tested model drugs permeation across the skin. As 
iontophoretic treatment periods for more than 8 h are not practical and applicable in 
most clinical settings, we did not consider longer delivery times here.  
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Surface charge of the nanocarrier (IV): 
One of the aims of this study was to investigate the effect of surface charge of the 
nanocarrier on model drug transport under iontophoretic current. For that purpose, 
we compared the drug transport from pegylated liposomes with reduced negative 
zeta potential value to that from highly negatively charged conventional liposomes. 
As expected, the highly negatively charged conventional liposomes (F1) led to 
slightly more efficient iontophoretic delivery of DS than pegylated liposomes with 
reduced surface charge (F2), indicating that the liposome charge can affect the 
outcome of iontophoretic treatment. Also, the enhancement factors and transport 
numbers of F2 were lower than that of F1. At the same time, passive drug fluxes 
from both the formulations were identical. This indicates that the higher 
iontophoretic flux of F1 liposomes could have only be related directly to the more 
pronounced mobility of the nanocarrier under electric current (electrorepulsion of 
liposome), not to changes in skin-liposome interaction, leading to improved 
diffusion of liposomes. 
 
 
 
Fig. 21. The in vitro transdermal permeation of DS across porcine full-thickness skin. A. The 
permeation curves of DS from solution formulation passively and under direct constant (DC) or 
pulsed current (PC). B. The liposome formulations with the highest passive (F3, passive) or 
iontophoretic flux (F4, DC). Mean ± SD, n=5-6. 
 
Type of the lipid vesicle (III): 
In a study of DS-loaded liposomes, the impact of the type of the vesicular system 
was determined on the permeation of loaded model drug under iontophoretic 
delivery. Thus, the drug permeation from conventional liposomes and two special 
vesicular systems, ultradeformable liposomes and ethosomes was compared. From 
all the tested lipid vesicle formulations, ultradeformable liposomes (F3) resulted in 
the highest passive flux but not the highest iontophoretic flux (Fig. 21B). At the 
same time, the highest iontophoretic flux was obtained with ethosomes (F4) under 
direct constant current (EDC=6.4 and EDC=2.4 for F4 and F3, respectively), although 
the passive transport of DS from ethosomes was inferior to the one from 
transfersomes. For transfersomes, open (non-occluded) administration has been 
proposed to be prerequisite to obtain maximum permeation enhancing effect as the 
driving force for penetration – transdermal hydration gradient – is eliminated by 
occlusive conditions (Cevc and Blume, 1992). At the same time as the application of 
iontophoretic current requires aqueous media around the electrodes, all our 
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permeation experiments were conducted under occlusion to prevent the evaporation 
of the buffer from the donor compartment. Interestingly, in our study occlusion did 
not abolish totally the penetration enhancing effects of the transfersomes compared 
to other tested lipid vesicles. Similar results were obtained when estradiol transport 
from transfersomes under occlusion was studied (Essa et al., 2004). 
 
 
Table 19. The results from the permeation experiments with DS solution and different lipid 
vesicle formulations (F1-F4). Mean, n=5-6. 
a steady-state flux; b transport number; c enhancement factor; d % of JPC of JDC – percent of steady-
state flux of pulsed current treatment from steady-state flux of constant current treatment 
 
Effect of current type (III-IV): 
In addition, the effect of current type was studied on the transdermal delivery of a 
drug loaded into nanocarriers. Constant current (DC) treatment is typically the most 
efficient in enhancing transdermal delivery of charged or ionic drugs, although it has 
some limitations, especially in long-term continuous use (see Section 2.2.2). 
Interestingly, in contrast to free drug delivery from solution, when using dispersions 
of FFA-loaded nanoparticles in the donor compartment, the application of pulsed 
current (PC) was equal or more efficient in carrying the FFA across the skin 
compared to the constant current (III). The cumulative amount of FFA delivered 
from the FA-PLGA nanoparticles across human epidermis with pulsed current was 
significantly higher than the amount transported with constant current (p<0.05). 
However, we were not able to detect any remarkable differences either in the 
intensity or depth of the fluorescence signal in the cryo-sectioned porcine full-
thickness skin after permeation studies without or with iontophoresis by the different 
current profiles (Fig. 22.). On the contrary, pulsed current treatment had no clear 
advantage over constant current treatment in combination with any liposome 
formulation (IV). The treatment was especially ineffective with liposomes with 
 
Treatment 
Jssa 
(nmol/h*cm3) 
Tnb Ec 
% of JPC 
of JDCd 
Solution 
Passive 2.78 ± 1.31 - - - 
DC 14.21 ± 7.51 8.13 x 10-4 ± 3.81 x 10-4 5.1 - 
PC 10.45 ± 4.27 7.47 x 10-4 ± 2.86 x 10-4 3.8 73.5 
F1 
Passive 1.11 ± 0.43 - - - 
DC 3.98 ± 1.78 2.13 x 10-4 ± 9.53 x 10-5 3.6 - 
PC 2.94 ± 0.90 2.10 x 10-4 ± 6.46 x 10-5 2.6 73.9 
F2 
Passive 1.11 ± 0.56 - - - 
DC 3.64 ± 1.12 1.95 x 10-4 ± 7.47 x 10-5 3.3 - 
PC 1.78 ± 0.72 1.27 x 10-4 ± 5.09 x 10-5 1.6 48.6 
F3 
Passive 1.44 ± 0.30 - - - 
DC 3.47 ± 1.23 1.86 x 10-4 ± 6.72 x 10-5 2.4 - 
PC 2.38 ± 0.64 1.70 x 10-4 ± 3.98 x 10-5 1.7 68.6 
F4 
Passive 0.71 ± 0.18 - - - 
DC 4.53 ± 1.59 2.43 x 10-4 ± 1.04 x 10-4 6.4 - 
PC 2.87 ± 1.82 2.05 x 10-4 ± 1.39 x 10-4 4.1 63.4 
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lower surface charge such as pegylated or ultradeformable liposomes, as seen from 
the % of JPC of JDC value (that show the percent of steady-state flux of pulsed current 
treatment from the steady-state flux of constant current treatment). Under alternating 
current (AC), model drug FFA was transported from nanoparticle dispersions across 
the skin similarly to solution formulation, with fluxes only slightly higher than with 
passive delivery (III). 
 
Skin type (III): 
The transdermal transport of free and nanoencapsulated FFA under passive and 
iontophoretic conditions was investigated in two skin barrier models of “golden 
standard” − human epidermis and full-thickness porcine skin. Both these skin 
models are histologically and biochemically very similar and the fluxes have been 
repeatedly demonstrated to correlate well (Godin and Touitou, 2007). However, 
when studying in vitro penetration of substances through the follicular route, the 
properties of porcine skin are believed to be superior to excised human skin, mainly 
due to the fact that the follicular reservoir of the human skin is significantly reduced 
after excision (Patzelt et al., 2008). Our study did not reveal any major differences in 
results with human epidermis and porcine full-thickness skin, but obviously the flux 
values remained lower and lag-times longer when delivering the hydrophobic FFA 
across full-thickness skin compared to the epidermal layer only.  
 
 
Fig. 22. Confocal laser scanning images of cross sections of porcine skin after permeability study 
without iontophoresis and with different iontophoretic current treatments. Fluorescence from FA-
PLGA  nanoparticles is represented in white colour. 
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Overall, in this study we did not establish any clear advantage from 
nanoencapsulation of drugs into nanocarriers with respect to drug permeation across 
the skin compared to free drug formulation, both in passive delivery or with any 
tested iontophoretic protocols. Nevertheless, it cannot be excluded that similar 
systems of combining nanocarriers and iontophoresis could have potential in other 
therapeutic regimens, e.g. aiming at depot formation in the skin after short-term (1-2 
h) iontophoresis, followed by sustained release of drugs into the systemic blood 
circulation over longer periods of time. 
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CONCLUSIONS 
 
In this study novel systems combining iontophoresis and ion-exchange fibers or 
drug-loaded nanocarriers were developed and tested for the controlled transdermal 
delivery of various therapeutics. The main conclusions are: 
 
1. Ion-exchange fibers are promising drug reservoir materials to retard the drug 
release and provide additional control into transdermal transport of small molecular 
weight drugs and peptides. The drug release from the fibers and the following 
transdermal flux can be controlled by modifying either the fiber type or the ionic 
composition of the external solution. Due to the high affinity of tested model drugs 
towards the ion-exchanger, the transdermal fluxes from the fibers remained lower 
compared to the respective fluxes from solution formulations.  
 
2. The use of pulsed current may offer significant benefit over constant current in 
the transdermal iontophoretic delivery of therapeutic peptides that have a tendency to 
adsorb into skin and inhibit electroosmosis as their main transport mechanism. 
Although the application of pulsed current did not result in the increase of 
transdermal flux of the cationic hydrophobic peptide leuprorelin across porcine 
epidermis compared to constant current, the significantly higher transport number 
demonstrated improved transport efficiency due to elimination of the inhibition of 
electroosmotic solvent flow.   
 
3. Although the tested drug-loaded nanocarriers – PLGA nanoparticles and lipid 
vesicles – were suitable for transdermal iontophoretic administration, regarding the 
colloidal properties, stability under iontophoretic current and drug release kinetics, 
no clear advantage was observed with respect to drug permeation from free drug 
formulations. Nanoencapsulation of model drugs led to reduced transdermal steady-
state fluxes and longer lag-times, both in passive and iontophoretic delivery 
regimens.  
 
4. This is the first study to systematically investigate the effect of iontophoretic 
current type on the transdermal permeation of a drugs loaded into nanocarriers. 
Based on our findings, polymeric nanoparticle-based formulations for transdermal 
iontophoretic delivery could benefit from the use of pulsed current instead of the 
traditional constant current. In contrast, traditional constant current iontophoresis 
should be applied in combination with the drug-loaded lipid vesicular nanocarriers. 
 
5. Several crucial formulation parameters have to be carefully considered when 
developing ion-exchanger or nanocarrier-based systems intended for transdermal 
iontophoretic drug delivery. Both the release and flux of drugs from the ion-
exchange reservoir are highly dependent on the ionic composition of the donor 
formulation. In our study, the presence of competing co-ions in the donor solution 
had a dominating impact on drug fluxes over the amount of the drug molecules 
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released from the fibers into the donor formulation. Iontophoretic drug transport 
from lipid vesicular nanocarriers is significantly affected by the composition and 
charge of the lipid bilayer. 
 
The major challenge in the development of new iontophoretic systems is to design 
relatively inexpensive and patient-friendly systems, while still maintaining the 
stability of drugs and providing efficient drug delivery. In this thesis, we 
demonstrated that ion-exchanger or nanocarrier-based drug reservoir systems are 
suitable to be combined with iontophoresis and that several of the above problems 
could be overcome by these systems. Although groundwork has been laid for the 
application of such combined approaches, there is a long way to determine the full 
potential of these systems in transdermal drug delivery.  
 
Today, ion-exchange materials are still mainly used for the purification and 
separation of compounds. More detailed and exhaustive studies are required to 
explore the benefits of such materials in drug delivery applications, including in 
iontophoretic drug delivery for drug release control, competing counter-ion removal 
or drug flux enhancement. In order to optimize iontophoretic drug delivery from 
systems based on ion-exchange materials, precise impact of all the physicochemical 
properties of the drug and electric current on drug release kinetics from ion-
exchangers has to be determined. Modeling and simulation to build predictive tools 
on the interactions between drug/ion-exchanger/external conditions, could be applied 
to facilitate the research in further realizing the utilization of these materials as drug 
carriers.  
 
The combined use of nanotechnology and active enhancement techniques such as 
iontophoresis is predicted to be one of the future strategies in further increasing the 
drug transport for dermal or transdermal administration. Combined with 
nanotechnology, iontophoresis could open up the transcutaneous route to new 
therapeutic areas and the range of drugs to be delivered by skin could be expanded to 
electrically neutral, hydrophilic, large or unstable molecules. Still further studies are 
needed to investigate the potential of follicular route for delivering therapeutics in 
nanocarriers into viable skin or systemic circulation. Also, as nanocarriers represent 
a heterogeneous group of drug vehicles with typically complex and multiple modes 
of drug transport, more investigations are warranted to fully understand the exact 
transport mechanism from each nanocarrier category, either in passive or 
iontophoretic delivery. Finally, the efficacy and safety of all such combined systems 
in humans requires thorough evaluation. 
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